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Abstract 
Zinc is the second most abundant transition metal in the body.  Despite the fact that hundreds of 
biomolecules require zinc for proper function and/or structure, the mechanism of zinc transport into 
cells is not well-understood.  ZnT and ZIP proteins are members of the SoLute Carrier (SLC) family 
of membrane transporters and are one of the principal family of proteins involved in regulating 
intracellular zinc concentration. ZnT (Zinc Transporters) decrease the cytosolic concentration of 
zinc, while ZIP (for Zinc or Iron regulated Proteins) transporters function to increase the cytosolic 
zinc concentration. Mutations in one member of the ZIP family of proteins, the human ZIP4 (hZIP4; 
SLC39A4) protein, can result in the disease acrodermatitis enteropathica (AE). AE is characterized 
by growth retardation, diarrhea, behavioral disturbances and neurological disorders.  While the 
cellular distribution of hZIP4 protein expression has been elucidated, the cation specificity, kinetic 
parameters of zinc transport, residues involved in cation translocation and structural details are 
unresolved questions.   
 
To elucidate cation specificity and kinetic parameters of zinc transport by hZIP4, we have 
established a high signal to noise zinc uptake assay following heterologous expression of hZIP4 in 
Xenopus laevis oocytes.  The results from our experiments have demonstrated that zinc, copper (II) 
and nickel can be transported by hZIP4 when the cation concentration is in the micromolar range.  
We have also identified a nanomolar affinity for copper (II) and zinc transport by hZIP4.  In 
contrast, under nanomolar conditions, nickel can bind, but is not transported by hZIP4.  Finally, 
labeling of hZIP4 with maleimide or DEPC indicates that extracellularly accessible histidine, but 
not cysteine, residues are required, either directly or indirectly, for cation uptake.  The results from 
our experiments describe at least two coordination sites for divalent cations and provide a new 
framework to investigate the ZIP family of proteins. 
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Members of the ZIP family of proteins are a central participant in transition metal homeostasis as 
they function to increase the cytosolic concentration of zinc and/or iron. However the lack of a 
crystal structure hinders elucidation of the molecular mechanism of ZIP transport proteins. We 
employed GREMLIN, a co-evolution based contact prediction approach in conjunction with the 
ROSETTA structure prediction program to construct a structural model of the human (h) ZIP4 
transporter. The resulting computational data is best fit by modeling hZIP4 as a dimer. Mutagenesis 
of residues that comprise a central putative hZIP4 transmembrane transition metal coordination site 
in the structural model alter the kinetics and specificity of hZIP4. Comparison of the hZIP4 dimer 
model to all known membrane protein structures identifies the twelve transmembrane monomeric 
PiPT, a member of the major facilitator superfamily (MFS), as a likely structural homolog.  
 
hZIP4 has eight transmembrane domains and encodes a large intracellular loop between 
transmembrane domains III and IV, M3M4. Previously, it has been postulated that this domain 
regulates hZIP4 levels in the plasma membrane in a zinc-dependent manner. To elucidate the zinc 
binding properties of the large intracellular loop of hZIP4, we have recombinantly expressed and 
purified M3M4 and showed that this fragment binds two zinc ions. Using a combination of site-
directed mutagenesis, metal binding affinity assays, and X-ray absorption spectroscopy, we 
demonstrated that the two Zn2+ ions bind sequentially, with the first Zn2+ binding to a CysHis3 site 
with a nanomolar binding affinity, and the second Zn2+ binding to a His4 site with a weaker affinity.  
Circular dichroism spectroscopy revealed that the M3M4 peptide is intrinsically disordered, with 
only a small structural change induced upon Zn2+ coordination. Our data supports a model in which 
the intracellular M3M4 domain senses high cytosolic Zn2+ concentrations and regulates the plasma 
membrane levels of the hZIP4 transporter in response to Zn2+ binding. 
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1.1 Zinc: An essential micronutrient for humans 
Zinc is the second most abundant transition metal found in the living organisms. However, the 
nutritional value of zinc was first realized in 1869, when the role of zinc was associated with 
Aspergillus niger’s growth1. It took almost another century to extend the importance of zinc to 
human health. In 1963, zinc was first speculated to have a nutritional value in human health2, 3. 
Later in 1973, the World Health Organization recommended the inclusion of zinc to the list of 
essential micronutrients. Since then, there have been extensive studies conducted on zinc deficiency 
and symptoms in humans. The total zinc found in an adult human is about two grams of zinc and 
its deficiency can cause growth retardation, weight loss, impaired immune system, hypogonadism, 
alopecia, diarrhea, neurological abnormalities and delayed wound healing2-5. Excess of zinc can 
cause vomiting, diarrhea, muscular cramp and nausea6. 
 
1.2 Zinc inside the cell  
Iron is the most abundant transition metal in the human body followed by zinc and copper. The 
total cellular concentration of zinc is in the micromolar range7. At the cellular level, zinc is 
associated with gene translation, gene transcription and cell division. Cellular Zn2+ deficiency 
impairs protein synthesis, cell growth and metabolism8, 9.  On the other hand, excess of free cellular 
Zn2+ can compete with other transition metal ions and thereby interfere with their function by 
causing protein-misfolding or aggregation, leading to cellular toxicity10. Therefore, the 
concentration of free zinc is tightly regulated inside the cells. Free zinc concentration in eukaryotic 
cell was found to be in picomolar range7, 11. Excess of zinc is compartmentalized into the storage 
granules, where zinc concentration can reach up to millimolar concentration12.  
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1.3 Zinc biochemical properties 
Zinc interacts with many cellular proteins and its functional importance has been associated with 
but not limited to the structural stability and catalytic activity of proteins. A proteomic study 
designed to identify Zn2+-binding human proteins suggested that about 10% of the human proteome 
could be Zn2+ interacting proteins13. More than 300 metalloenzymes, which are essential for cellular 
metabolic activities have been associated with zinc14. In fact, zinc is the only transition metal which 
can interact with all the six classes of enzymes: oxidoreductase, transferase, hydrolase, lyase, 
isomerase and ligase15, 16. Zinc has a unique electron distribution in the outer most orbital, which 
allows it to interact with ligands in a multiple coordination geometry arrangement (Figure 1). A 
detailed study of zinc coordination geometry in proteins shows that zinc prefers a tetrahedral 
geometry (82%) over trigonal (14%) or octahedral (4%) geometry when zinc is important for the 
stability of protein structure17. However, when zinc plays a catalytic role, the relative preference 
for tetrahedral geometry (58%) decreases whereas the preference for a trigonal (31%) and 
octahedral geometries (11%) increase17.  
 
Zinc has very high redox potential, which makes it inert in biological systems. The lack of redox 
properties separates zinc from other transition metals such as iron and copper, as zinc is less likely 
to cause oxidative damage in vivo13. Because of the unique redox properties, zinc can play a 
protective role against oxidative damage to the cell. For example, the Copper-Zinc superoxide 
dismutase is the first line of cellular defense mechanism to counter the increase of free radicals18, 
19.  As a high sulfhydryl interacting metal ion, zinc also protects the antioxidant proteins20. Zinc 
competes with other redox sensitive metal ions such as iron and copper to displace or reduce their 
intracellular concentrations20. Zinc provides the structural stability to DNA transcription factors8. 
Furthermore, zinc helps to increase the metallothionein concentration, which scavenges free 
radicals21.  
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Figure 1. Zn2+ coordination geometries 
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1.4 Proteins important for zinc cellular distribution  
Of the total two grams of zinc in an adult human body, only 0.1% zinc is present in the plasma and 
the rest is stored at the cellular level22. The mechanism of cellular zinc uptake, trafficking and 
export is a complex field which is largely unexplored23.  Zinc transport was initially hypothesized 
to be mediated by co-transport with either cysteine or histidine, as zinc binds these amino acid 
residues with high affinity24. An alternate theory of zinc transport by zinc specific membrane 
transport proteins was introduced later, which gained more support upon the identification of the 
first mammalian zinc transporter gene25, 26. Subsequent studies have identified two classes of zinc 
transporters; those which mediate a net increase (ZIP; Zrt- and Irt-like proteins; SLC39A) or a net 
decrease (Znt; solute- linked carrier 30; SLC30A) in cytosolic zinc levels (Figure 2)23, 27. Other than 
zinc transport proteins, metallothinein proteins are important for intracellular zinc trafficking28.  
 
1.4.1. Metallothionein 
Metallothionein proteins regulate the zinc trafficking and distribution in the cell whereas zinc 
transport proteins change the zinc concentration by importing or exporting zinc to the various 
cellular or extracellular compartments21, 28, 29. The role of metallothonein in physiology has been 
studied extensively and strong correlations with cellular protective mechanism against oxidative 
stress was found28. It has also been suggested that the zinc protected thiol groups of metallothionein 
reacts with oxygen and nitrogen reactive species and in the process releases zinc28, 30. The cells 
respond to the increased cellular zinc concentration with increased metallothionein concentration 
as well as a change in the expression of other protective metalloproteins including ZIP and ZnT 
proteins31. 
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Figure 2. Cellular Zn2+ homeostasis 
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The structural studies of metallothionein protein have suggested that the protein has two domains 
named α-domain and β-domain32. The α-domain of the metallothionein protein binds to four zinc 
ions through eleven cysteines, whereas the β-domain coordinates three zinc ions through nine 
cysteine residues32. The binding affinity of metallothionein proteins to zinc can be up to 10-13M. 
Further, it has been hypothesized that the α-domain is relevant to zinc transfer across various 
cellular compartments, while the β-domain has other physiological role such as metal transfer to 
other metalloproteins.  
 
1.4.2 ZnT proteins  
ZnT proteins are grouped under a larger cation diffusion facilitator family of proteins33. In humans, 
ZnT family of proteins consist of ten member proteins, which are designated as ZnT1-ZnT1027. 
The zinc transporter proteins are located in the plasma membrane of various cellular compartments, 
and they function to reduce the free cytosolic zinc concentration by exporting Zn2+ to the 
extracellular milieu or into the storage vesicles27. Based on hydropathy analysis, it was suggested 
that ZnT proteins have 6 transmembrane (TM) domains and cytosolic N- and C-termini with the 
exception of ZnT534. The ZnT5 protein has a long N-terminus, which has nine transmembrane 
domains fused together34. The ZnT proteins have a long histidine rich intracellular loop between 
TM4 and TM535, 36. It has been suggested that the large intracellular loop acts as a zinc sensing 
domain and it is important for zinc transport activity34. More recently, elucidation of the crystal 
structure of the bacterial efflux zinc transporter YiiP which has 25-30% sequence homology with 
mammalian ZnT zinc transporters has provided important insight into this class of proteins37.  The  
bacterial zinc transporter YiiP functions as a homodimer37. Additionally, an extensive study in 
MCF-7 cells using bimolecular fluorescence complementation technique revealed that ZnT1, 
ZnT2, ZnT3, ZnT4, ZnT5 and ZnT7 form homodimers, whereas a heterodimer between ZnT5-
ZnT6 was also observed38. Also, an analysis of hZnT4 expression in human breast epithelial cells 
showed small dimer population under non-reducing denaturing condition39. 
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ZnT proteins are Zn2+/H+ exchangers40, 41. Further, based on the study of YiiP protein in 
proteoliposomes, the stoichiometry analysis suggested that ZnT exchanges proton and zinc in 1:1 
ratio40. Inspection of the YiiP crystal structure has revealed that D45, D49 of TM2 and H153, D157 
of TM5 forms binuclear zinc binding site within the TM region37. Therefore, based on sequence 
homology it was hypothesized that the YiiP corresponding conserved aspartic acid and/or histidine 
residues in hZnT of TM2 and TM5 are important for zinc transport. Later, it was also shown that 
mutation of these residues in mammalian ZnT results in the elimination of Zn2+ transport activity 
41. Consequently, aspartic acid and histidine residues of TM2 and TM5 are also important for the 
metal selectivity in ZnT proteins. More recently, ZnT10 has been shown to transport manganese as 
well42. The sequence homology suggested that the conserved histidine position of TM2 is replaced 
with an aspartic acid residue which may have contributed to the change in metal selectivity of 
ZnT1042.  
 
1.4.3 ZIP proteins 
Similar to ZnT proteins, the ZIP proteins are also members of the cation diffusion facilitator family 
of proteins. However unlike ZnT proteins, ZIP proteins increase the cytosolic zinc concentration 
by importing zinc from extracellularly or zinc storage vesicles. The ZIP family of proteins has 14 
member proteins in humans that are further classified into four major classes based on sequence 
similarity36. The four subclasses of ZIP family of proteins are ZIPI, ZIPII, gufA and LIV-1 (Table 
1)36. The subfamily ZIPI consists mainly of plant genes, yeast and protozoan whereas ZIPII 
subfamily consists of mainly nematodes and mammalian genes43. The gufA and LIV-1 subfamilies 
were introduced later where the gufA subfamily is based on sequence similarity with the gufA gene 
in Myxococcus xanthus and the LIV-1 subfamily is related to the oestrogen-regulated gene44. 
Amongst all the four subgroups, the LIV-1 group is found only in eukaryotes and is the largest 
subclass comprising of  ZIP4, ZIP5, ZIP6, ZIP7, ZIP8, ZIP10, ZIP12, ZIP13 and ZIP1436.  
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Table 1. ZIP protein distribution in human body 
 
 ZIP 
Protein 
Tissue Distribution Cellular Localization 
 ZIP4 Small intestine, stomach, 
colon,  kidney, pancreas45 
Plasma membrane45 
ZIP12 Brain46 
 
 
ZIP6 Breast, prostate, kidney47 Plasma membrane47 
 
ZIP8 Pancreas, placenta, lung, 
liver, testis, thymus48, 49 
Plasma membrane, lysosome, endosomes49 
ZIP14 Liver, heart, pancreas, thyroid 
gland50 
Plasma membrane, mitochondria, 
endosome, lysosome50, 51 
ZIP5 Liver, kidney, intestine, 
pancreas52 
Plasma membrane52 
ZIP10 Testis, breast53, 54 
 
 
ZIP7 Brain, prostate, liver53, 55, 56 
 
Golgi, endoplasmic reticulum56 
ZIP13  
 
Golgi57 
ZIP1 GI tract, liver, heart, spleen, 
prostate58 
Plasma membrane, endoplasmic 
reticulum58, 59 
ZIP3 Prostate60 
 
Plasma membrane60 
ZIP2 Prostate, uterine61 
 
Plasma membrane61 
ZIP9 Prostate53 
 
Golgi62 
ZIP11  
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The organ distribution of human ZIP proteins is listed in Table 1. Based on hydropathy analysis, 
ZIP proteins have been predicted to have eight TM domains with both N- and C-terminus are 
extracellular63. Additionally, ZIP proteins have a large histidine rich intracellular loop between 
TM3 and TM4 and a highly variable N-terminus. It has been suggested that the histidine rich 
intracellular domain may act as a zinc sensor. Similar to ZnT, it was predicted that ZIP protein may 
function as dimer. Later, it was reported that the LIV-1 member protein hZIP13 formed a 
homodimer57. Similarly, dimer hZIP2 was observed when it was over expressed in HEK293 cells64. 
Further, the specificity and selectivity of ZIP proteins varies (Table 2). 
 
ZIP protein mediated Zn2+ transport is ATP independent. Multiple attempts have been made to 
elucidate the driving force for Zn2+ transport by ZIP proteins. For example, hZIP1 mediated Zn2+ 
transport was hypothesized to be pH dependent as Zn2+ transport is inhibited at lower pH65. 
However, the Km for Zn2+ transport under reduced pH conditions for hZIP1 has not been studied 
which may help to elucidate more detailed hZIP1 mediated Zn2+ transport mechanism. Similarly, 
hZIP2 mediated Zn2+ transport was stimulated by the presence of bicarbonate61. It was suggested 
that phosphorylation of some of the residues in hZIP7 drives Zn2+ transport66. In contrast, hZIP8 
and hZIP14 were proposed to be Zn2+/HCO3- symporters as bicarbonate transport was inhibited by 
4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS)67. However, the driving force for other 
ZIP proteins remain unknown. 
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Table 2. The specificity and selectivity of ZIP proteins 
 
 
 
 
 
 
Protein Heterologous 
system 
Specificity study of Zn2+ transport 
hZIP1 K562 
Erythroleukemia 
cells 
Zn2+ transport inhibited by six fold Ni2+ 59 
mZIP1 HEK293 cell Zn2+ transport was modestly inhibited by 50 fold excess of 
Cu2+, Cd2+, Mn2+, Co2+, Ag1+, Mg2+, Ni2+ and Fe2+ 68 
hZIP2 K562 
Erythroleukemia 
cells 
Zn2+ transport inhibited by six fold Cd2+,Cu2+ and Mn2+ 59 
mZIP2 HEK293 cell Zn2+ transport was modestly inhibited by 50 fold excess of 
Cu2+, Cd2+, Mn2+, Co2+, Ag1+, Mg2+, Ni2+ and Fe2+ 68 
mZIP3 HEK293 cell Zn2+ transport inhibited by tenfold Cu2+, Cd2+, Mn2+, Co2+, 
Ag1+, Mg2+ and Ni2+ 68 
mZIP4 HEK293 cell Zn2+ transport was not inhibited by 50 fold excess of Cu2+, 
Cd2+, Mn2+, Co2+, Ag1+, Mg2+, Ni2+ and Fe2+ 69 
mZIP5 HEK293 cell Zn2+ transport was not inhibited by 50 fold excess of Cu2+, 
Cd2+, Mn2+, Co2+, Ag1+, Mg2+, Ni2+ and Fe2+ 52 
mZIP7 Yeast Transports Zn2+ 56 
mZIP8 
 
MFF cells Transports Zn2+, Cd2+ and Mn2+ 70 
X.laevis oocytes Transports Zn2+ and Cd2+ 71 
Cd2+ transport was inhibited by three fold excess of Hg2+, 10 
fold Cu2+ and 30 fold Pb2+ 71 
rZIP10 LLC-PK1 cells Zn2+ transport was inhibited by Cd2+ 72 
mZIP11 MDCK cells Transports Zn2+ and Cu2+ 73 
mZIP12 N2a cells Transports Zn2+ 46 
hZIP13 293T cells Transports Zn2+ 57 
mZIP14 X.laevis oocytes Transports Cd2+, Fe2+, Mn2+ and Zn2+ 74 
Fe2+ transport inhibited by 10 fold excess of Cd2+, Co2+, Mn2+, 
Ni2+, Pb2+, or Zn2+ 74 
Zn2+ transport was inhibited by 10 fold excess of Cd2+ 74 
Mn2+ was inhibited by 10-fold excess of Cd2+, Co2+, Fe2+, 
Ni2+, Pb2+ and Zn2+ 74 
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1.5 hZIP4 protein 
The hZIP4 protein is a member of the LIV-1 subfamily and has two major isoforms.  Among the 
two known isomers of the hZIP4 protein, the most abundant isoform has 647-amino acids whereas 
the second less abundant isoform has 622-amino acids75. Similar to other ZIP proteins, hZIP4 has 
been predicted to have eight transmembrane domains with both N- and C-terminus facing the 
extracellular side (Figure 3)63.  hZIP4 also has a characteristic long histidine rich intracellular loop 
between TM3 and TM4 (M3M4)45, 75. The highly variable N-terminus amongst ZIP proteins, is 
predicted to be comprised of 327 amino acids in hZIP4.  Similar to the M3M4 domain, the N-
terminus of hZIP4 is also rich in histidine and cysteine, which suggests that these residues may 
have an important role in zinc transport. Further, hZIP4 protein has a highly conserved sequence 
(HSVFEGLAVGIQ) in TM4 that is believed to be important for zinc selectivity and transport68.  
 
hZIP4, a member of the LIV-1 subfamily, plays an important role in Zn2+ homeostasis. hZIP4 was 
first identified due to its involvement in the lethal, childhood Zn2+ deficiency disease acrodermatitis 
enteropathica (AE)45. So far, there have been 32 mutations reported in hZIP4 that were responsible 
for AE, of which 13 mutations were missense mutations (Table 3)76, 77. hZIP4 is the primary Zn2+ 
transporter expressed in the stomach, small intestine, colon and kidney45, 69. AE is an autosomal 
recessive genetic disorder whose symptoms include skin lesions, diarrhea, growth retardation, 
neurological disorders, severe infections and, if left untreated, death78. The symptoms of AE can be 
reversed with increased dietary Zn2+ supplementation78, 79. In addition to its normal tissue 
distribution, the surface expression of hZIP4 is increased in pancreatic, liver and brain cancer cells, 
where hZIP4 surface expression has been correlated with metastatic stage and survival times80-83. 
In cancer cells, hZIP4 overexpression was shown to increase the expression of growth factors as 
well as matrix metalloproteinases, which activates factors implicated in cancer cell proliferation 
such as the interleukin 6 (IL-6), signaltransducer and activator of transcription 3 (STAT3) 
pathways84. An analysis of the COSMIC human genome database showed 31 missense 
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Figure 3. Predicted schematic diagram of the human ZIP4 protein. The full-length protein is 
displayed where histidine residues are shown as orange circles and cysteine residues as blue circles. 
The first and last residues of the transmembrane domains, as predicted by hydropathy analysis, are 
shown. 
 
 
 
 
 
 
 
 
 
 
 
 
Histidine                            Cysteine 
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Table 3. Reported missense hZIP4 mutations in cancer and AE patients 
 
 
 
 
Location in 
protein 
Mutations reported in cancer 
patient (COSMIC database) 
Mutations reported in Acrodermatitis 
enteropathica patients 
 Missense 
mutation 
Location Missense 
mutation 
Impact to protein 
function 
N termini L28M Lung C62R85  
L32V Large intestine R95C86  
P107L Skin N106L45  
P133L Skin P200L75 Reduced Vmax75 
T268M Large intestine, 
pancreas 
Q303H86  
P290L Haematopoietic and 
lymphoid 
C309Y45  
TM1   G330D45 Cellular 
mislocalization45 
TM2 S366R Lung L372P45 Reduced protein 
expression45 
  G374R75 Reduced protein 
expression75 
TM3 F420L Skin   
TM4 G516C Large intestine G512W76  
M4M5   G526R75 Reduced Vmax75 
TM5 F570L Liver   
F578T Liver   
M6M7 S585I Large intestine   
TM7 L590P Large intestine G595V87  
Y599C Thyroid   
D604N Lung   
A608T Pancreas   
M7M8 P617L Stomach   
TM8 G627A Endometrium G630R45 Reduced protein 
expression45 
L637P Oesophagus   
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substitution muations to date in N-termini of hZIP4, some of which are listed in Table 3. More 
recently, it was proposed that ZIP4 mediated Zn2+ transport can stimulate glucose dependent insulin 
secretion in pancreas88. Similarly, hZIP6 and hZIP7 have been shown to be important for 
maintaining insulin level in pancreas89.  
 
The most studied ZIP4 protein is derived from mouse (mZIP4). hZIP4 has about 70% sequence 
homology with mZIP4. The transmembrane domains of hZIP4 and mZIP4 are highly conserved69. 
However, there are some key differences between these two proteins.  First, the N-terminal domains 
of mZIP4 and hZIP4 are only 68% identical and the histidine-rich, putative extracellular zinc 
binding domain is not conserved.  Second, the histidine-rich, putative intracellular zinc binding 
domain is not conserved between mZIP4 and hZIP4. From a functional standpoint, it has been 
suggested that mZIP4 is a zinc-selective transporter, because zinc transport is not substantially 
inhibited by the addition of fifty-fold excess of other transition metals69. Also, both mZIP4 and 
hZIP4 undergo post-translational modifications. Predicted phosphorylation sites for mZIP4 and 
hZIP4 indicated that mZIP4 undergoes phosphorylation at T367, Y369 and R503 whereas hZIP4 
undergoes phosphorylation at T357, Y359 and S49090. Earlier it was observed that phosphorylation 
of another LIV-1 member protein, hZIP7, resulted in hZIP7 mediated Zn2+ transport91. However, a 
similar study on hZIP4 or mZIP4 has not been conducted and the role of phosphorylation in hZIP4 
needs further study.   
 
The N-terminus of hZIP4 is rich in cysteine and histidine residues. Further, the N-terminus has 
three HxxH and one CxxC motifs, which are similar to conserved zinc binding motifs in zinc finger 
proteins92.  Earlier, it was proposed that the N-terminus may have an important role in Zn2+ transport 
because of its ability to increase the local Zn2+ concentration. Interestingly, multiple mutations have 
been reported on the N-terminus of AE patients. It has also been suggested that the N-terminus of 
hZIP4 acts as a Zn2+ sensing domain93. However, both the mZIP4 and hZIP4 have been reported to 
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undergo ectodomain cleavage near its  “PALV” signature sequence when cells are starved of Zn2+ 
93. The “PALV” sequence is believed to be a metalloproteinase cleavage site, and it is highly 
conserved across the LIV-1 family of proteins. Interestingly, mutations at G340D, G384R, and 
G643R results in reduced ectodomain cleavage processing; the mechanism of which is not exactly 
known. Therefore, it is possible that the N-terminus of hZIP4 has other important roles which may 
or may not be relevant to the Zn2+ transport. More recently, the N-terminus of hZIP4 has been 
suggested to have a prion like structure94. It has been predicted that there are at least three potential 
glycosylation sites on the N-terminus of hZIP4 which are N192, N219 and N27295. The detection 
of hZIP4 in HEK293 cells indicating two distinct  hZIP4 populations and treatment of cells with 
N-Glycosidase F resulted in a singular population of hZIP4 indicating expression of two differently 
glycosylated hZIP4 protein population96. However, the effect of glycosylation on hZIP4 mediated 
Zn2+ transport has not been shown. LIV-1 proteins have also been predicted to have a 
metalloprotease motif (HExPHExGD) located in TM5 suggesting that ZIP proteins may also 
participate in proteolytic activities27. 
 
Similar to the N-terminal ectodomain of hZIP4, the intracellular characteristic long loop between 
TM3 and TM4 also has two HxxH motifs. Studies with hZIP4 and its mouse homologue have 
shown that surface expression of the transporter is regulated by the cytosolic concentration of Zn2+ 
96, 97. At high cytosolic Zn2+ concentrations, ZIP4 undergoes Zn2+-dependent endocytosis, thereby 
reducing ZIP4 levels in the plasma membrane96, 97. At even higher Zn2+ concentrations, hZIP4 is 
ubiquitinated, presumably at a highly conserved lysine residue within a large intracellular loop 
between TM3 and TM4 and is further subjected to proteasomal degradation96. Earlier, it has been 
observed that when the cellular concentration of zinc is high, hZIP4 undergoes protein 
ubiquitination and subsequent degradation. The mutagenesis of all the histidine residues (H438, 
H441, H443, H446 and H448) within the loop between TM3 and TM4 eliminates hZIP4 
ubiquitination96. The Zn2+-dependent ubiquitination and degradation required the presence of a 
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histidine-rich domain located on the large cytosolic loop, leading to the hypothesis that the 
intracellular domain acts as a Zn2+ sensor that is involved in regulating hZIP4 levels in the plasma 
membrane. Interestingly, the Zn2+ sensing intracellular domain also responds to Cd2+ by initiating 
proteolytic degradation of ZIP4 protein but not Cu2+, Mg2+, Ni2+, Co2+ and Fe2+ 96. 
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2 The Human ZIP4 Transporter Has Two Distinct Binding 
Affinities and Mediates Transport of Multiple Transition 
Metals 
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2.1 Introduction 
hZIP4 plays key roles in human zinc homeostasis as well as in the initiation and progression of 
pancreatic cancer. Also, earlier experiments have suggested that the ZIP family of proteins differ 
in cation selectivity. Therefore, our objective was to elucidate the cation specificity of hZIP4 
uptake.  We expressed hZIP4 in Xenopus laevis oocytes and developed a radioisotope uptake assay 
to test the functionality of the protein. We have also investigated which extracellular-accessible 
residues are important for zinc uptake.  The results from these experiments provide a novel insight 
into the function of hZIP4, while introducing a series of unresolved questions in regards to the 
mechanism of cation transport.  
 
Lastly, elucidating the function of free or loosely bound Zn2+ in the cytosol as well as in intracellular 
compartments remains important; however, the ability to modulate Zn2+ levels in vivo in a time-
resolved manner remains elusive98. Free Zn2+ has long been implicated in various signaling 
pathways99, and recently fertilization of oocytes has been shown to trigger “zinc sparks” that serve 
to initiate meiosis at the beginning stages of embryotic development100. In this study, we have 
developed new methodologies to simulate fluctuations in Zn2+ concentrations, which  facilitates the 
understanding of complex signaling processes. 
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2.2 Materials and method 
2.2.1 Reagents 
The SLC39A4 (hZIP4) gene and the mMessage mMachine SP6 kit were purchased from Invitrogen 
(Carlsbad, CA).  Restriction endonucleases were purchased from New England Biolabs, Inc. 
(Ipswich, MA).  The radioisotopes 65ZnCl2 63NiCl2, and 64CuCl2, were obtained from Perkin Elmer 
(Waltham, MA), Oak Ridge National Labs (Oak Ridge, TN) and Washington University of St. 
Louis (St. Louis, MO), respectively.  Maleimide was purchased from Alfa Aesar, Inc (Ward Hill, 
MA).   
 
2.2.2 Plasmid construct 
The hZIP4 gene, containing 647 residues, was subcloned, with a Strep tag (WSHPQPEK) at the C-
terminus, into the Xenopus laevis oocyte pTLN vector101.   Two unique restriction sites NcoI at the 
N-terminus and BglII at the C-terminus were used for unidirectional insert incorporation.   The 
entire hZIP4-Strep tag sequence was verified by DNA sequencing. 
 
2.2.3 Preparation of Xenopus laevis oocytes for in situ expression of hZIP4 
Oocytes were surgically removed and isolated from Xenopus laevis following a protocol approved 
by the Worcester Polytechnic Institute Animal Care and Use Committee. Female Xenopus laevis 
were anesthetized with tricaine (1.5 g per liter for 1 hour). Oocytes were extracted by partial 
ovariectomy and were digested with 2 mg/ml collagenase in ORI buffer (90 mM NaCl, 2 mM KCl, 
2 mM CaCl2, 5 mM MOPS, pH 7.4) for 4-5 hours at 18˚ C on an orbital shaker102. After digestion, 
oocytes were incubated with Ca2+-free ORI buffer (90 mM NaCl, 2 mM KCl, 5 mM MOPS, pH 
7.4) for 10 minutes.  Following this step, the oocytes were washed exhaustively; first, with Ca2+-
free ORI buffer and second, with ORI buffer.  Oocytes were stored at 18˚ C in ORI buffer with 20 
µg/ml gentamycin until needed. 
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2.2.4 In vitro expression of hZIP4 
The pTLN plasmid containing the full-length hZIP4 gene with the strep tag was linearized with 
Mlu1 and purified using the High Pure PCR Product Purification Kit (Roche Applied Science). 
mRNA was prepared and purified using the SP6 mMessage mMachine kit according to 
manufacturer’s instructions. Purified mRNA was quantified on a NanoDrop™ ND-2000c 
Spectrophotometer (Thermo Scientific Co.).  A 25 ng aliquot of mRNA in 50 nL DEPC-treated 
H2O was injected into each oocyte and was incubated at 18˚ C in ORI buffer with 20 µg/ml 
gentamycin for three days prior to measurements.  For negative controls, 50 nL DEPC H2O was 
injected into oocytes. 
 
2.2.5 Immunofluorescence microscopy 
Three days post hZIP4 mRNA injections, oocytes were preincubated with 0 or 10 µM ZnCl2 for 1 
hour in uptake assay buffer, washed and fixed in 4% (w/v) paraformaldehyde solution for 20 
minutes at room temperature. DEPC H2O injected oocytes were used as a negative control. Oocytes 
were washed with phosphate-buffered saline (PBS) two times and cryoprotected in 30% (w/v) 
sucrose in PBS overnight at 4˚ C. The oocytes were frozen in OCT medium (Tissue-Tek) and cut 
into 25 μm sections. The sections were mounted on positively charged slides (VWR Micro Slides) 
and blocked in 5% BSA solution in PBS for 1 hour at room temperature. The oocytes sections were 
washed with PBS two times and incubated with Strep-tactin antibody (IBA GmbH) conjugated 
with Chromeo-488 dye for 1 hour at 37˚ C. The sections were washed with PBS two times and then 
mounted in fluorescence protective mounting medium (KPL Mounting Medium). Fluorescence 
images were taken using a Leica DM LB-2 microscope with a 20X objective.    
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2.2.6 Uptake assay 
Uptake experiments were loosely based on established protocols103.  Oocytes, injected with either 
hZIP4 mRNA or DEPC H2O, were washed and pre-incubated in 750 μL uptake buffer (90 mM 
NaCl, 10 mM HEPES and 1 mM ascorbic acid at pH 7.4) for 30 min.  The uptake assay was initiated 
upon addition of radioisotope (63NiCl2, 64CuCl2, or 65ZnCl2) and was quenched by removal of five 
to eight oocytes into cold uptake buffer followed by extensive washes.  All 64CuCl2 uptake assays 
were performed in the absence of ascorbic acid.  Under these experimental conditions, copper is 
predominantly in the +2 oxidation state as determined using the copper-bathocuproinedisulfonic 
acid standard absorbance assay.  Each oocyte was solubilized by vigorous vortexing in 1% (w/v) 
sodium dodecylsulfate (SDS).  Total radioactivity was measured using a Beckman LS6500 Multi-
Purpose Scintillation Counter with Scintisafe-30% liquid scintillation cocktail (Fisher Scientific).    
Counts from DEPC H2O-injected oocytes were subtracted from hZIP4 mRNA-injected oocytes 
unless otherwise indicated.  Counts per minute were converted to picograms (pg) or femtograms 
(fg) using the following equation: 
𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴𝐴 (𝑝𝑝𝑝𝑝 𝐴𝐴𝑜𝑜 𝑓𝑓𝑝𝑝) = CPM × dilution factor × half − life correction factorSpecific Activity � DPMpg or fg� × efficiency  
where CPM (counts per minute) were the raw data obtained from each oocyte, dilution factor is the 
total concentration of radioactive and non-radioactive metal ion divided by the concentration of 
radioactive cation, half-life correction factor is the half-life of radioisotope divided by the half-life 
of radioisotope minus time elapsed and the specific activity [in disintegrations per minute (dpm)/pg 
or fg] as provided by the manufacturer.  The half- life for 63Ni+2, 64Cu+2, and 65Zn+2 are 100 years, 
12.7 hours and 244 days, respectively.  For a more accurate conversion of cpm to dpm, it was 
experimentally determined that the efficiency of our scintillation fluid/counter for 63Ni+2 was 74.3% 
while the efficiency for 64Cu+2 and 65Zn+2 was 68.4%. 
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Data was fit to the equation:   
𝑦𝑦 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚 × [𝑋𝑋2+]𝑛𝑛 𝐾𝐾𝑚𝑚𝑛𝑛  + [𝑋𝑋2+]𝑛𝑛 
where Vmax is the maximal velocity, [X2+] is the concentration of divalent metal ion, Km is 
the concentration of divalent metal at one-half Vmax and n is the Hill co-efficient. 
 
2.2.7 Maleimide and DEPC labeling of hZIP4 
Oocytes were pre-incubated for thirty minutes in varying concentrations of either DEPC or 
maleimide.  Prior to initiation of the uptake assay with 3µM 65ZnCl2, half of the oocytes 
were washed with cold uptake buffer.  Reaction initiation, quenching and radioisotope 
quantification was performed as described earlier (2.2.6).  In order to determine whether 
exposure to DEPC is toxic to the oocytes, the resting membrane potential was determined 
using a TEC 03X Standard System two electrode voltage clamp set-up (NPI Electronics). 
 
2.2.8 Driving force for hZIP4 mediated 65Zn2+ transport 
In order to elucidate the driving force for hZIP4 mediated Zn2+ transport, the uptake buffer 
was modified and Zn2+ transport was tested as described below.  
 
2.2.8.1 Proton as a driving force 
The uptake buffer was prepared with varying pH from 5.5 to 8.5. We observed that oocytes 
tend to be leaky at a pH lower than 5.5 and higher than 8.5. The uptake assay was performed 
as described before. 
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2.2.8.2 Sodium Chloride as a driving force 
NMDG was used to test whether sodium contributes to Zn2+ transport mediated by hZIP4. 
The equimolar concentration of sodium chloride was replaced with NMDG. The pH was 
set to 7.4 using acetic acid and potassium hydroxide. 
 
2.2.8.3 Sodium as a driving force in the presence / absence of chloride 
Equimolar concentrations of sodium chloride were replaced with potassium chloride to test 
the role of sodium in hZIP4 transport activity in the presence of chloride ions. The pH was 
brought to 7.4 using potassium hydroxide and hydrochloric acid. On the other hand, 
equimolar concentrations of sodium acetate were replaced with NMDG to test the role of 
sodium in hZIP4 transport activity in the absence of chloride. The pH was brought to 7.4 
using acetic acid and sodium hydroxide. 
 
2.2.8.4 Multiple anion and cation as a driving force  
Multiple conditions were tested to define the driving force parameters. The conditions are listed in 
Table 4. The uptake experiment was performed at pH 7.4. 
 
2.2.9 Zn-Cage compounds and Zn2+ transport in X. laevis oocytes 
65Zn2+ (Perkin Elmer) was incubated with a 1000x Zn-Cage compound, nitrilotriacetic acid (NTA) 
and iminodiacetic acid (IDA) for 15 minutes. The oocytes injected with hZIP4 RNA or DEPC 
treated water were washed three times with overnight chelex-100 treated uptake buffer and were 
suspended into the uptake buffer having 250nM final concentration of 65Zn2+. The oocytes in 65Zn2+ 
solution, 65Zn2+-NTAde Cage (65Zn2+-NTA decarboxylation photoCage), 65Zn2+-NTA and 65Zn2+-
IDA were irradiated with UV-LED for three minutes followed by 57 minutes incubation at room 
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temperature in the dark. A batch of oocytes in 65Zn2+-Cage solution was incubated in dark for 60 
minutes without irradiation with UV-LED light. After 60 minutes, each oocyte was washed four 
times with uptake buffer and solubilized in 200 µl of 1 % (w/v) sodium dodecyl sulfate solution. 
The solubilized oocyte was supplemented with scintillation fluid (Scintisafe-30%, Fisher 
Scientific) and the radioactivity was measured using a Beckman LS6500 Multi-Purpose 
Scintillation Counter. 
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Table 4. Conditions tried to elucidate the driving force for hZIP4 mediated Zn2+ transport   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 NaCl 
(mM) 
NMDG-
Cl 
(mM) 
NaCl : 
HCO3-  
(mM) 
NaCl : 
HCO3-  
(mM) 
NaGlu 
(mM) 
NaGlu: 
HCO3- 
(mM) 
NaGlu: 
HCO3- 
(mM) 
NaCit 
(mM) 
KGlu 
(mM) 
Sodium 
Chloride 
(NaCl) 
90  - 80  70  - - - - - 
NMDG-Cl - 90  - - - - - - - 
Sodium 
Bicarbonate - - 10  20  - 10  20  - - 
Sodium 
Gluconate 
(NaGlu) 
- - - - 90  80  70  - - 
Sodium 
Citrate 
(NaCit) 
- - - - - - - 90  - 
Potassium 
Gluconate 
(KGlu) 
- - - - - - - - 90  
HEPES 10  10  10  10  10 10 10 10 10  
Ascorbic 
Acid 1  1  1  1  1  1  1  1  1  
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2.3 Results 
2.3.1 hZIP4 localizes on Xenopus laevis oocytes membrane surface 
To establish the localization of the heterologously expressed hZIP4 in Xenopus laevis oocytes, 
expression of hZIP4 was detected in sections of paraformaldehyde-fixed oocytes using a 
Chromeo488-labeled anti-Strep antibody.  Immunofluorescence was observed in mRNA injected 
oocytes before and after exposure to 10 μM ZnCl2, but was not visible in DEPC-H2O injected 
controls, demonstrating localization at the plasma membrane (Figure 4).  
 
2.3.2 hZIP4 transports zinc in X. laevis oocytes 
Following insertion of the full-length hZIP4 gene with the strep tag added onto the C-terminus into 
the pTLN vector and mRNA synthesis, our initial objective was to generate a zinc uptake assay 
with high specificity and robust signal to noise ratio.  The longer, 647 amino acid protein was 
investigated throughout the course of these experiments as it has been shown that the homologous 
longer protein is the predominant species in mouse69.  Xenopus oocytes were injected with varying 
amounts of hZIP4-Strep mRNA and the radioactive 65Zn2+ uptake was measured three to six days 
post-injection.  During the course of all assays, DEPC H2O was injected for negative controls.  
Optimal radioisotope uptake was observed following injection of 50 ng mRNA of hZIP4 where the 
assay was initiated three days post-mRNA injection (Figure 5).  It was observed during the course 
of these experiments that injection of a larger amount of hZIP4 mRNA resulted in a decreased 
viability of oocytes after 3 days of incubation period. 
 
Following optimization of the amount of hZIP4-Strep mRNA to inject in oocytes and identification 
of the best time to measure radioisotope uptake in mRNA injected oocytes, we were interested in 
determining the range of zinc which would result in a linear amount of radioisotope uptake over 
time.  Therefore, we initiated the uptake assay using a final concentration of ZnCl2 
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Figure 4. Representative images of three oocytes injected with hZIP4 mRNA tagged with Strep 
tag on the C-terminus and probed with Chromeo488-conjugated anti-Strep antibody. Anti-Strep 
specific staining is present in oocytes injected with hZIP4 mRNA before (left) and after (right) 
exposure to 100 μM ZnCl2. No staining is observed in DEPC-H2O injected oocytes (center). The 
arrow indicates the surface of the oocyte. 
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Figure 5. Evaluation of 65Zn2+ radioisotope uptake assay in hZIP4 expressing oocytes. (A) Oocytes 
were injected with either 50 ng of mRNA of hZIP4-Strep in 50 nl of DEPC H2O or 50 nl of DEPC 
H2O. Three days postinjection, 65Zn2+ uptake was measured as described in Experimental 
Procedures over the course of 2 h. Oocytes were removed every 30 min for a total of four time 
points. A final 65Zn2+ concentration of 21.75 μM was used for this experiment. Radioisotope uptake 
is shown for DEPC H2O-injected (black) and hZIP4-Strep mRNA-injected (gray) oocytes. Counts 
per minute were converted to picograms of 65Zn2+. Data originated from five to eight oocytes; 
values are means ± SEM. (B) Oocytes, injected with 25 ng of hZIP4-Strep mRNA, were incubated 
with varying amounts of ZnCl2 [(◆) 0.49 μM Zn2+, (■) 44.7 μM Zn2+, and (▲) 105.1 μM Zn2+]. 
The assay was quenched every 30 min up to 120 min, and data originated from five to eight oocytes; 
values are means ± SEM.  
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from 0.49-105.1 μM (Figure 5).  Analysis of the results from these experiments demonstrated that 
zinc uptake is roughly linear over two hours over this range of zinc concentration and that zinc 
uptake is proportional to the amount of Zn2+ in the uptake assay.  
 
2.3.3 Determination of Km and Vmax for hZIP4-mediated zinc uptake 
Our next objective was to determine the Km for zinc transport by hZIP4.  Therefore, we measured 
Zn2+ uptake with varying concentrations of radioisotope in the uptake assay buffer for 60 minutes.  
Under our experimental conditions, two distinct Km values for zinc could be elucidated.  In both 
cases, zinc uptake was plotted as a function of the concentration of zinc in the assay buffer (Figure 
6A and 6B).  
 
An analysis of the results from our experiments demonstrated that at low zinc concentrations, the 
Km was 76 ± 5 nM, where n = 3.6 ± 0.6 and Vmax = 94 ± 6 pg/oocyte/hour.  A second Km for zinc 
was calculated in the micromolar range at 1.4 ± 0.3 µM, where n is 1.2 ± 0.3 and Vmax = 850 ± 60 
pg/oocyte/hour (Figure 6B).  Our results demonstrated that Vmax varied for each experiment.  This 
is directly attributable to changes in surface expression of hZIP4 in oocytes.  However, the values 
for Km and n were consistent over a series of repeated experiments at both micromolar and 
nanomolar concentrations of zinc. The representative data for measuring transport affinity were 
conducted on same batch of oocytes.   
To elucidate the rate of hZIP4-mediated zinc uptake in the range of both Km values, zinc uptake 
was measured as a function of time in the nanomolar and micromolar range (Figure 6C and 6D, 82 
nM and 21.75 μM Zn2+, respectively).  Under both of these conditions, we observed an 
approximately linear increase in zinc uptake over the course of the two hour experiment.  In 
addition, the difference in radioactivity when zinc uptake was measured in the nanomolar 
concentration was at least four times higher in the mRNA injected vs. DEPC H2O injected oocytes. 
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Figure 6. Zinc affinity and transport by hZIP4. The transport parameters, Km and Vmax, for hZIP4 
was elucidated at low (A) and high (B) concentrations of zinc by measuring amount of Zn2+ uptake 
into oocytes injected with hZIP4-Strep mRNA over one hour in assay buffer which contained 
varying amounts of ZnCl2.  At low concentration the Km and n were calculated to be 76 ± 5 nM and 
3.6 ± 0.6 respectively, whereas at high concentration Km and n were calculated to be 1.4 ± 0.3 µM 
and 1.2 ± 0.3 respectively.  The rate of Zn2+ uptake into oocytes was measured as a function of time 
at 82 nM (C) and 21.75 μM (D) over the course of two hours.   
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It is noteworthy that the Zn2+ transport in hZIP4 injected oocytes varies with different batch of 
oocytes and mRNA preparation. The time course experiment for Zn2+ transport experiment was 
conducted on different batch of oocytes than the oocytes used for measuring transport affinity.  
 
2.3.4 hZIP4 may transport multiple transition metals 
The cation specificity of three of the fourteen human ZIP proteins has been examined61, 67, 70.  These 
proteins have unique transport properties despite the fact that their primary sequences are highly 
homologous.  Therefore, we hypothesized that hZIP4 might transport cations other than zinc.  In 
order to test this hypothesis, our first objective was to determine whether any divalent cations would 
inhibit hZIP4 mediated 65Zn2+ uptake.  While this is not a direct measurement of cation transport, 
this experiment would provide insight into which cations should be tested for hZIP4-mediated 
cation uptake.  For this experiment, oocytes expressing hZIP4 were pre-incubated with 600 μM of 
various transition metals for one hour .  As a positive inhibition control, 600 μM cold Zn2+ was pre-
incubated with oocytes expressing hZIP4.  The zinc uptake assay was initiated upon addition of 3 
µM 65Zn2+ and the length of time for the uptake assay was one hour.  Uptake of 65Zn2+ was 
measured.  All of the data was normalized to 65Zn2+ uptake in the absence of any competing metal.  
It was expected that cation(s) which inhibited or competed with zinc uptake would decrease 65Zn2+ 
uptake.  In contrast, cations which did not inhibit or compete with hZIP4-mediated 65Zn2+ uptake, 
would demonstrate no change in 65Zn2+ uptake.   
 
The results from our experiments demonstrated that addition of 600 μM cold Zn2+ inhibited 96 ± 1 
% of 65Zn2+ uptake (Figure 7).   Addition of 600 μM of the divalent cations Ba2+, Cd2+, Co2+, Fe2+, 
Mg2+, and Mn2+ had no significant effect on 65Zn2+ uptake.  In contrast, addition of 600 μM Cu2+ 
and Ni2+ decreased hZIP4-mediated 65Zn2+ uptake.  The addition of 600 μM Ni2+ inhibited 35 ± 8 
% of 65Zn2+ uptake while the addition of 600 μM Cu2+ inhibited 96 ± 1 % of 65Zn2+ uptake. 
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Figure 7. Competition of 65Zn2+ uptake with a series of divalent cations in WT hZIP4 expressing 
oocytes.  To determine which divalent cations inhibited hZIP4-mediated 65Zn2+ uptake, oocytes 
expressing hZIP4 were pre-incubated in 600 µM cold ZnCl2, BaCl2, CdCl2, CoCl2, CuCl2, FeCl2, 
MgCl2, MnCl2, or NiCl2 in the uptake assay buffer.  The uptake assay was initiated by adding 3.0 
µM 65ZnCl2.  
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It is noteworthy that ascorbic acid was absent in Zn2+ transport assay when Cu2+ was used as a 
competing divalent metal. The uptake assay in the presence of Cu2+ and ascorbic acid resulted in 
non-viable and leaky oocytes. The presence of ascorbic acid reduces Cu2+ to Cu1+. Our colorimetric 
assay measuring the amount of Cu1+ generated from an excess of Cu2+ (600 mM) in the presence 
of 1 mM ascorbic acid and 1 mM copper-bathocuproinedisulfonic acid confirmed that ascorbic acid 
undergoes oxidation to generate almost 1 mM of Cu1+.  The Cu1+ generated in the presence of 
ascorbic acid damages the oocyte membrane possibly by lipid peroxidation reaction.    
   
2.3.5 hZIP4 can transport nickel  
Considering that our competition experiment does not directly test for cation uptake other than zinc, 
our next objective was to directly measure whether Cu2+ or Ni2+ could be transported by hZIP4. 
Therefore, 63Ni2+ uptake was measured using our established uptake assay except that 65Zn2+ was 
replaced with 63Ni2+.  
 
As a first step, we examined whether nickel uptake was linear over time.  At low concentrations 
(4.76 nM 63Ni2+), there is a measurable amount of nickel which accumulates with the hZIP4-
injected oocytes which does not increase over the two hour uptake assay (Figure 8A).  In contrast, 
when the concentration of Ni2+ is increased in the uptake assay (5.25 μM), nickel uptake is 
approximately linear over two hours (Figure 8B). After obtaining these results, our next 
experiments were performed with the goal to determine the Km of Ni2+ at both nanomolar and 
micromolar concentrations.  When our uptake assay contained low amounts of 63Ni2+, an analysis 
of our experiments determined that nickel uptake follows Michaelis-Menten kinetics, where the  
Km is 1.1 ± 0.1 nM and n = 1.3 ± 0.1 where Vmax is 102 ± 4 fg/oocyte/hour (Figure 8C).  At the 
micromolar range of Ni2+, an analysis of our experiments revealed that the Km is 2.9 ± 0.3 μM and 
n = 1.5 ± 0.2 where Vmax is 95 ± 5 pg/oocyte/hour (Figure 8D).  In addition, the difference in 
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Figure 8. Nickel affinity and transport by hZIP4.  A. 63Ni2+ uptake for oocytes injected with either 
25 ng mRNA of hZIP4-Strep in 50 nL DEPC H2O or 50 nL DEPC H2O was measured as described 
in the Materials and Methods section over the course of two hours using a final concentration of 
4.76 nM 63NiCl2.  B.  In a similar manner, Ni2+ uptake was measured using a final concentration of 
5.25 μM NiCl2.  C.  The Km and Vmax of 63Ni2+ was elucidated at nanomolar concentrations of 63Ni2+.  
The Km and n were calculated to be 1.1 ± 0.1 nM and 1.3 ± 0.1 respectively.  D.  The Km and Vmax 
of Ni2+ was elucidated at micromolar concentrations of Ni2+.  The Km and n were calculated to be 
2.9 ± 0.3 μM and 1.5 ± 0.2 respectively.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ni2+ Concentration (nM)
0 2 4 6 8
N
i2
+  
U
pt
ak
e 
(f
g)
 / 
oo
cy
te
 / 
30
 m
in
ut
e
0
20
40
60
80
100
120
Ni2+ Concentration (µM)
0 2 4 6 8 10 12 14 16
N
i2+
 U
pt
ak
e 
(p
g)
 / 
oo
cy
te
 / 
ho
ur
0
20
40
60
80
100
120
Time (Minute)
30 60 90 120
N
i2
+  
U
pt
ak
e 
(p
g)
 / 
oo
cy
te
 
0
20
40
60
80
100
120
Time (Minute)
30 60 90 120
N
i2
+  
U
pt
ak
e 
(f
g)
 / 
oo
cy
te
0
20
40
60
80
100
120
A B 
C D 
36 
 
radioactivity when the nickel uptake was measured in the nanomolar concentration was at least four 
times higher in the mRNA injected vs. DEPC H2O injected oocytes. 
 
2.3.6 hZIP4 transports copper (II) in oocytes 
Considering our experimental result that a 200-fold excess of Cu2+ inhibits more than 95% of 65Zn2+ 
uptake, our goal was to directly examine Cu2+ uptake.  In a similar manner as the previous 
experiments, the first step for these experiments was to measure the rate of Cu2+ uptake at low (6.6 
nM) and high (10 μM) concentrations (Figures 9A and 9B).  Under each of these conditions, the 
amount of Cu2+ uptake increased at an approximately linear rate during the two hour experiment.  
Therefore, our next experiment was to calculate the Km for Cu2+ uptake.  Similar to both zinc and 
nickel, we could elucidate two distinct Km values for copper uptake when the uptake was plotted 
as a function of Cu2+ concentration.  Furthermore, the difference in radioactivity when copper (II) 
uptake was measured for a nanomolar concentration was at least four times higher in the mRNA 
injected vs. DEPC H2O injected oocytes.  We were able to calculate a Km of 7.9 ± 1.3 nM where n 
= 3.2 ± 1.9 and Vmax is 1721 ± 373 fg/oocyte/hour when Cu2+ was added to the uptake assay in 
nanomolar amounts (Figure 9C).  Using a higher concentration of Cu2+, the Km was calculated to 
be 1.20 ± 0.09 μM where n = 2.2 ± 0.3 Vmax is 1530 ± 30 pg/oocyte/hour (Figure 9D).  
 
2.3.7 Extracellular histidine residues are important for hZIP4 mediated 65Zn2+ transport 
It was initially hypothesized that zinc transport into cells was mediated by co-transport with either 
histidine or cysteine residues as zinc binds with high affinity to these residues.  This theory became 
mutually unexclusive when the first mammalian zinc transporter gene was identified in 1995104.  
Based on this initial hypothesis and the fact that zinc coordinates tightly to both cysteine and 
histidine, we hypothesized that covalent labeling of extracellular-accessible cysteine and/or 
histidine residues would disrupt 65Zn2+ uptake. 
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Figure 9. Time course and kinetics of hZIP4-mediated Cu2+ uptake.  A. Cu2+ uptake was measured 
over two hours at a final concentration of 6.6 nM in femtograms.    B.  Cu2+ uptake was measured 
at a final concentration of 10 μM over two hours in picograms.  C.   Cu2+ uptake was measured 
after one hour at varying concentrations of Cu2+ to quantify the transport properties of this cation.  
The Km and n were determined to be 7.9 ± 1.3 nM and 3.22 ± 1.9 respectively.  D.   64Cu2+ uptake 
was measured after one hour at micromolar concentrations of 64Cu2+ to quantify the transport 
properties.  At these concentrations, the Km and n were calculated to be 1.2 ± 0.1 μM and 2.2 ± 0.3 
respectively.   
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Maleimide and DEPC have been used previously to examine the role of extracellular-accessible 
cysteine and histidine residues, respectively, following heterologous expression in Xenopus laevis 
oocytes105, 106.  Oocytes, injected with either hZIP4 mRNA or DEPC H2O, were pre-incubated with 
maleimide and DEPC H2O for 30 minutes.  The oocytes were then washed exhaustively with uptake 
assay buffer and the uptake assay was initiated upon addition of 65Zn2+.  Under these experimental 
conditions, no free maleimide or DEPC is present in the uptake assay.  No change in zinc uptake 
was observed following labeling with 1 mM or 10 mM maleimide (Figure 10).  In contrast, while 
no change was observed in65Zn2+ uptake with 1 mM DEPC, a significant decrease of zinc uptake 
was observed following labeling of oocytes expressing hZIP4 with 10 mM DEPC.   
 
In order to further explore the relationship between zinc uptake and labeling of free cysteine and 
histidine residues, maleimide and DEPC were not washed out prior to the uptake assay. Therefore, 
maleimide or DEPC is available to react with residues in hZIP4 which may move from an 
inaccessible to accessible state during the conformational change of hZIP4 which is correlated with 
zinc transport.  
 
Under these conditions, there was an increase in zinc uptake when 1 mM maleimide was present in 
the uptake assay during zinc transport.  This increase in zinc uptake in the presence of malemide 
was abolished when the concentration of maleimide was increased to 10 mM.  No significant 
change in zinc uptake was observed when 1 mM DEPC was present in the uptake assay.  In contrast, 
there was a significant decrease in zinc uptake when 10 mM DEPC was included in the uptake 
assay when compared to having the 10 mM DEPC washed out prior to the radioisotope uptake 
assay.  In order to assess whether the addition of 10 mM DEPC had a toxic effect on oocytes, the 
resting membrane potential of oocytes pre-incubated in 0 or 10 mM DEPC for 60 minutes was 
determined using a two-electrode voltage clamp set-up.  No significant difference in membrane 
potential was observed between these two experimental conditions.  It has already been 
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Figure 10. Extracellular histidines are involved in zinc translocation.    The uptake data for DEPC 
or Maleimide treated hZIP4 expressing oocytes was normalized to non-treated oocytes. Black bars 
represent zinc uptake after labeling reagents were removed prior to uptake assay.  Grey bars are the 
results when the labeling reagents were present during the uptake assay. At least one asterisk 
indicates that there is a statistically significant difference in uptake values between the experimental 
and control experiments by t test.  Two asterisks indicate a statistically significant difference 
(ANOVA p value <0.05) in uptake values between two experimental conditions. 
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demonstrated that exposure of 10 mM DEPC to oocytes overnight has no effect on the resting 
membrane potential of oocytes107. 
 
2.3.8 Multiple factors were tested to define the driving force for hZIP4 mediated 65Zn2+ 
transport 
In order to elucidate the driving force of hZIP4 mediated zinc transport, we performed a series of 
pH and ion replacement experiments. Analysis of the results show that hZIP4 activity is pH 
independent (Figure 11A). Our ion replacement assay shows that zinc transport is inversely 
proportional to sodium chloride and sodium acetate concentration (Figure 11B, 11C). In the event 
of replacing sodium chloride with potassium chloride, the uptake experiment results were 
inconclusive (Figure 11D). Replacement of sodium chloride with sodium gluconate or potassium 
gluconate was also inconclusive.  Finally, replacement with sodium citrate significantly reduces 
the hZIP4 mediated transport (Figure 12). It is also noteworthy, that equimolar replacement of 
sodium chloride with sodium citrate makes the intracellular pH acidic. This is also true with sodium 
acetate. With the possible effect on intracellular pH for sodium citrate and sodium acetate, we can’t 
rule out the possibility of change in uptake conditions are actually due to the change in ion gradient 
and not because of change in intracellular pH. 
 
2.3.9 hZIP4 expressing X.laevie oocytes can be used for Zn2+ photocage compound in 
evaluating their application in biological system 
The feasibility of using photocaged Zn2+ in biological systems was demonstrated by measuring 
Zn2+ transport following the heterologous expression of the human zinc transporter ZIP4 in X. laevis 
oocytes. In this experiment (Figure 13), we incubated oocytes expressing hZIP4 or water-injected 
controls with 250 nM 65ZnCl2, [65Zn(NTAdeCage)]1- in the absence of light,  [65Zn(NTAdeCage)]1- 
exposed to light, [65Zn(NTA)]1- exposed to light or 65Zn(IDA)]1- exposed to light. Future 
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Figure 11. Effect of pH, salt concentration on hZIP4 mediated Zn2+ transport. The uptake assay 
was carried out with 3µM Zn concentration for 1 hour. A) Oocytes were incubated in uptake buffer 
with varying pH from 5.5 to 8.5. B) Oocytes were incubated with varying sodium chloride 
concentration. Sodium Chloride was replaced with equimolar concentration of NMDG, C) Oocytes 
were incubated with varying concentration of sodium acetate. Equimolar concentration of sodium 
acetate was replaced with NMDG. D) To test the possibility of sodium being driving force NaCl 
was replaced with equimolar concentration of Potassium Chloride.  
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Figure 12. Effect of different buffers on hZIP4 mediated Zn2+ transport. The uptake assay was 
carried out with 6µM Zn concentration for 1 hour. Oocytes were incubated in uptake buffer with 
varying conditions at pH 7.4.  
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Figure 13. Evaluation of hZIP4 expressing oocytes as a model system to test photocaged Zn2+ in 
biological system. Oocytes were subjected to 65Zn2+ by incubating them with 250 nM 65ZnCl2 or 
250 nM 65ZnCl2 in the presence of 250 µM of NTAdeCage, NTA or IDA. The assay was performed 
as described previously. Each bar represents the data from the analysis of 9 to 12 oocytes. The 
uptake values shown are the mean values with standard error 
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experiments will address the kinetics of metal ion release from [Zn(NTAdeCage)]1- since the rate 
of uptake in this assay depends both on the uncaging kinetics and the kinetics of the transport 
protein. For these experiments, water-injected oocytes were subtracted from mRNA injected 
oocytes. Under these experimental conditions, free 65Zn2+, uncaged 65Zn2+ (by light) or 65Zn2+ in the 
presence of the photocage product (IDA) had transport rates which were similar. In contrast, 65Zn2+ 
coordinated to NTA or 65Zn2+ coordinated to the photocaged complex in the absence of light were 
transported by hZIP4 at a lower rate. The results suggest that both tetradentate chelators bind 65Zn2+ 
tightly, which inhibits transport by hZPI4. Upon photolysis of [65Zn(NTAdeCage)]1-, 65Zn2+ 
becomes available for uptake by the oocytes. 
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2.4 Discussion 
To investigate the specificity and kinetic parameters of hZIP4, we used Xenopus laevis oocytes as 
a platform to express this protein. While oocytes do have an endogenous zinc efflux mechanism, it 
has previously been shown that zinc efflux is independent of the extracellular zinc concentration 
which may contribute to our experimentally determined kinetic parameters103.  We have directly 
demonstrated that hZIP4 can transport Zn2+.  Furthermore, Cu2+ and Ni2+ inhibit hZIP4-mediated 
zinc uptake when these cations are present in 200 fold excess amounts.  In contrast, the divalent 
cations Ba2+, Cd2+, Co2+, Fe2+, Mg2+, and Mn2+ had no significant effect on 65Zn2+ uptake.  While 
this data is inconsistent with previous data which suggested that the mZIP4 protein is a Zn2+ cation 
transporter, it has been recently suggested that the ZIP family of proteins may have broader 
substrate translocation capability since hZIP14 can transport a variety of divalent cations69, 74.  
Furthermore, it is important to note that from our experiments we can only conclude that Ba2+, 
Cd2+, Co2+, Fe2+, Mg2+, and Mn2+ do not inhibit hZIP4-mediated 65Zn2+ uptake.  We cannot make 
any conclusions on whether these cations can be transported by hZIP4.  It has been shown that Fe2+ 
does not inhibit hZIP14-mediated 109Cd2+ uptake, but that Fe2+ can be transported by hZIP1474. 
Therefore, it is possible that hZIP4 could mediate the transport of one or more of the above named 
cations which do not inhibit 65Zn2+ transport.  For example, if there is more than one mechanism 
for cation translocation which do not compete with each other, we would expect similar results as 
in Figure 7 for the cations which do not inhibit 65Zn2+ uptake.  Alternatively, if the rate of transport 
for one of these cations is sufficiently fast, that it would not inhibit 65Zn2+ uptake, we would also 
observe no change in 65Zn2+ uptake upon addition of this cation in our cation competition 
experiment.  Our subsequent experiments have demonstrated that both Cu2+ and Ni2+ can be 
transported by hZIP4 when these cations are present in micromolar quantities.  The apparent 
affinities for each of these cations are in the low micromolar range.   
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A careful analysis of our experimental results has also uncovered a second binding affinity for 
65Zn2+, 63Ni2+, and 64Cu2+.  At this concentration, 65Zn2+ and 64Cu2+ are transported by hZIP4 as 
shown by the increase in radioisotope uptake over time.  In contrast, 63Ni2+ has a nanomolar binding 
affinity, but does not appear to be transported as there is no increase in radioisotope uptake over 
time.  Combined, this data suggests that there are at least two distinct coordination sites within 
hZIP4.  The simplest explanation is that the high affinity for each cation is for one site while the 
low affinity value is for a second cation coordinating site.  However, our data cannot directly 
resolve whether this is the case.  More importantly, a variety of groups have determined that the 
free concentration of zinc in cells is somewhere between 5 pM and 1 nM, while the free zinc 
concentration in plasma is estimated to be between ~0.1-1 nM108, 109.  Therefore, considering the 
high affinity site, this could have physiological relevance.  This is an unresolved question which 
would require further experiments both in vivo and in vitro.  Alternatively, it could be possible that 
our observed increase in radioactivity over time at low concentrations of Cu2+ and Zn2+ is due to a 
long time course of cation binding to hZIP4.  We consider this unlikely as this would likely be 
observed in our nickel uptake assay in the nanomolar concentration range.  Therefore, based on our 
experimental results, it appears that zinc and Cu2+ can be transported at low concentrations, while 
the coordination of Ni2+ does not result in transport, hence there is no increase in Ni2+ uptake over 
time (Figure 8A).  
 
It is interesting to further examine the observation that low concentrations of 63Ni2+ bind but are not 
transported by hZIP4.  In contrast to either Zn2+ or Cu2+, there is no cooperativity for Ni2+ in the 
nanomolar range. We propose that there is a coordination geometry where the binding of nickel 
does not lead to translocation, but where both copper and zinc can be released for transport.  Ni2+ 
prefers an octahedral coordination geometry while Zn2+ and Cu2+ prefer tetrahedral and tetragonal 
coordination geometries, respectively110.  Perhaps the transport of Ni2+  in the nanomolar 
concentration range is blocked due to differences in coordination geometry110.   
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It is important to note that an analysis of our data cannot exclude other possibilities.  One possibility 
is that nickel coordinates to a regulatory site and not a putative transport site as this would result in 
no nickel transport.  Alternatively, the nanomolar affinity site might require a conformational 
change for subsequent cation translocation.  If both Cu2+ and Zn2+ coordination induces a sufficient 
conformational change to promote translocation, whereas coordination of nickel does not induce a 
sufficient conformational change for cation translocation, a similar experimental result would be 
observed.   
 
Finally, considering that zinc was originally hypothesized to be co-transported by histidine or 
cysteine residues, our objective during the course of our next set of experiments was to determine 
whether covalent labeling of either of these residues would inhibit 65Zn2+ uptake.  Our data suggests 
that freely accessible cysteine residues, which are on the extracellular side of the membrane are not 
a rate-limiting step in 65Zn2+ uptake as transport is not inhibited upon addition of high 
concentrations of maleimide (Figure 10).  In contrast, addition of DEPC prior to the uptake assay 
has a significant effect on 65Zn2+ uptake.  This suggests that histidine residues on the extracellular 
side of the protein contribute to zinc transport across the plasma membrane.  It is important to note 
here that DEPC may also label histidine residues which are water accessible, but are located within 
the transmembrane domains.  When DEPC is incubated with hZIP4-injected oocytes, both before 
and during the uptake assay when compared to washing out DEPC prior to the uptake assay, there 
is an added decrease in zinc uptake.  We speculate that this added decrease in zinc uptake is due to 
a conformational change of hZIP4 which exposes one or more previously inaccessible histidine 
residues for labeling.  Alternatively, labeling of histidine residues may “lock” hZIP4 in a 
conformation where further zinc uptake is not possible.  A hydropathy analysis of the hZIP4 gene 
sequence shows that there are seven extracellular histidine residues, while the transmembrane 
domains encode an additional four histidine residues (Figure 3).  Although, DEPC mostly modifies 
histidine residues, it is possible that it can also label lysine, tyrosine, cysteine, arginine, serine and 
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threonine residues111.  DEPC labeling of one or more of these residues contribute to the decline in 
zinc uptake in our experimental conditions. 
 
It is worthwhile to use the results from these experiments to speculate on the mechanism of cation 
selectivity of hZIP4.  The ionic radii of Ni2+, Cu2+, and Zn2+ are 83, 87 and 88 pm, respectively.  
Each of the other cations tested are either smaller (Fe2+:  75 pm, Co2+: 79 pm, Mn2+: 81 pm) or 
larger (Cd2+: 109 pm, Ba2+:  149 pm) than the three cations which are transported by hZIP4 with 
the notable exception of Mg2+ (86 pm).  However, whereas the preferred donor atom for Mg2+ is 
oxygen, the preferred donor atoms for Ni2+, Cu2+, and Zn2+ are either sulfur or nitrogen.  Our 
covalent modification experiments with DEPC support our proposal that histidine residues 
contribute to coordinating these cations and could be involved in cation translocation.  This 
speculation should be used cautiously as the ionic radii described above are for de-hydrated ions.  
Hydration of these transition metals during translocation would change an analysis of our results. 
 
In order to identify the driving force conditions, we tested a series of conditions. It is now evident 
from the experimental results (Figure 10) that extracellular accessible histidine residues are 
important for zinc transport activity. Furthermore the pKa of histidine under physiological condition 
is 7.8. Both of these factors lead us to hypothesize that a change in extracellular pH would lead to 
a change in uptake. Although, an analysis of result (Figure 11A) shows that change in pH is not 
affecting zinc transport, one needs to be careful in extrapolating these results. To measure the pH 
contribution in Zn2+ transport, we used HEPES buffer, which has buffer capacity of 6.8-8.2. On the 
other hand, replacing sodium chloride with different ions did not help us to identify the driving 
force; replacement with sodium acetate and sodium citrate showed significant decreases in uptake. 
Since sodium acetate and sodium citrate are known to decrease the intracellular pH, the change in 
uptake could be due to a change in intracellular composition.  
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In conclusion, our study reveals that hZIP4 is a metal ion transporter which can transport Zn2+, 
Ni2+, and Cu2+.  Transport is either directly or indirectly mediated by accessible extracellular 
histidine residues.  Our results, combined with those from other laboratories, suggest that the ZIP 
family of proteins have a more diverse set of substrates than originally postulated and that in order 
to understand the functional significance of each of these proteins, it may be useful to directly 
measure transport for each member of the ZIP family of proteins.  However, it is important to 
acknowledge that our experiments have not been performed in the native environment of hZIP4 
and thus one must be careful in translating our results to physiological function.  In vivo it is worth 
noting that mutations in hZIP4 result in a zinc deficiency disease and mutations in the copper 
transport protein (CTR) family result in copper deficiency diseases112. Therefore, while hZIP4 is 
unlikely to be a main avenue of cellular copper uptake, hZIP4 is essential for maintaining cellular 
homeostasis of zinc. 
 
Lastly, we have tested in situ application of a new strategy to release metal ions from a chelating 
ligand using a photodecarboxylation reaction. NTAdeCage binds Zn2+ with sub-pM affinity and 
exhibits a reduction in metal binding affinity after efficient uncaging with 365 nm light. We have 
applied NTAdeCage to a Zn2+ uptake assay with hZIP4, which demonstrates this photocage can be 
used to study the zinc induced complex cellular signaling mechanisms. 
 
 
 
 
 
 
 
 
50 
 
 
 
 
 
 
 
 
 
 
 
 
3. Computational modeling and functional studies provide a 
structural scaffold for the zinc transporter hZIP4 
 
 
 
 
 
 
 
 
 
 
Note: Computational modeling studies were done in collaboration with David Baker’s lab at the 
University of Washington, Seattle, WA 98195. I thank Sergey Ovchinnikov, Dr. Hetunandan 
Kamisetty and Dr. David Baker for the computational model experiments and results.   
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3.1 Introduction 
ZIP member proteins have been shown to transport a variety of transition metals including Fe2+, 
Zn2+, Cu2+, and Cd2+ 74. Also, complementation studies have provided some evidence of residues 
of mechanistic importance 113, 114. However, direct examination of residues of functional importance 
or cation selectivity has not been shown. In chapter 2, we demonstrated that an excess of Ni2+ and 
Cu2+ could inhibit Zn2+ transport mediated by hZIP4. Furthermore, both Ni2+ and Cu2+ could be 
transported by hZIP4 in addition to Zn2+. To further explore the residues of functional importance 
for hZIP4, we determined that covalent labeling of extracellular water accessible histidine residues 
(DEPC) but not free cysteine residues (maleimide) inhibited Zn2+ translocation. Based on our 
earlier results, we set out to explore the role of transmembrane histidine residues in transition metal 
transport. We mutated each of the TM histidine residues into alanine residues and conducted kinetic 
studies for each mutant. Analysis of our experimental results demonstrate that although conserved 
histidine residues are not required for hZIP4 function, mutation of these residues can affect the zinc 
transport kinetics of hZIP4 protein. Additionally, our results also suggested that a highly variable 
residue contributes to cation translocation. Based on our results, we hypothesized that 
transmembrane histidine residues can influence the zinc translocation pathway. 
 
To further explore the zinc translocation pathway in hZIP4 protein, we also took the advantage of 
recent progress in predicting residue pair contacts in a protein structure using co-evolution data to 
generate a first molecular model of hZIP4 using Rosetta in combination with co-evolution data115, 
116. The model protein structure generated by Rosetta ab initio structure method uses constraint 
database generated by the combinations of various computational tools, which are explained below.  
 
1) Generation of a multiple sequence alignment (MSA) database is the first and one of the 
most important steps for making a model protein structure using the Rosetta ab initio 
method117. The higher the sensitivity and accuracy of the MSA database, the higher the 
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accuracy of co-evolution based protein structure prediction117. MSA is a technique to 
visualize the relationship between residues of two or more protein sequences. In general, 
most techniques used in generating the MSA database are based on the conservation of 20 
amino acids along with known secondary and tertiary protein structures, catalytic sites, 
active motifs, post-translational modifications and other properties of proteins. However, 
each algorithm technique has a different sensitivity, speed and precision. For example, 
MUSCLE and MAFFT are two of the most popular tools to generate MSA databases that 
also uses conservation and coevolution as a parameter118, 119. One problem with these tools 
is that when sequence identity falls below threshold, the sequence is excluded from the 
database. The exclusion of this sequence all together results in reduced sensitivity as well 
as precision. To overcome this problem, a more sensitive probabilistic technique based 
models have been developed, which are based on the likelihood for insertion, deletion, and 
mutation of an amino acid residues in a given protein sequence and aligned sequences120. 
One of the most popular probabilistic bases models is the hidden Markov model (HMM). 
The HMM based models are position specific and they calculate the probability of an 
amino acid at a particular position121. The result of this analysis is used as initial constraints 
in predicting the residue-residue contacts.  
 
2) HMM-based models are of great value in predicting the topology of protein. However, 
HMM based models use very simple topologies. HMM based MSA learning models limit 
the estimations of interactions to the neighboring amino acid residues, which results in  
overemphasis of the distribution of amino acids rather than the sequence of the protein. 
Therefore, a HMM model identified MSA database is further optimized to derive a more 
global relationship between a particular amino acid residue with the rest of protein. 
Generative REgularized ModeLs of proteINs (GREMLIN) is one of the algorithms that 
used HHM model identified MSA database to generate global statistical model that 
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simultaneously captures the conservation and co-evolution patterns in the input 
alignment116. Strongly co-evolving residue pairs as identified by this approach are highly 
likely to be in contact with each other in the three dimensional structure 116. The predicted 
co-evolved residues are used to generate the contact map. The contact map is a three 
dimensional representation method for predicted residue-residue interactions of a protein. 
 
3) Finally, the Rosetta ab initio structure prediction program is used to generate a three 
dimensional protein structure. The program identifies local sequences that are similar to 
other solved protein structures and uses them to generate a three dimensional structure. To 
reduce the sampling space in protein model prediction, the energy function constraint along 
with predicted residue-residue contacts and transmembrane helices are used. The Rosetta 
ab initio protocol consists of two stages: in the initial stage (“centroid”) side-chains are 
represented by fixed center-of-mass atoms allowing for rapid generation and evaluation of 
various protein-like topologies; the second stage (“full-atom”) places all-atom sidechains 
into a starting topology and iteratively refines the model until a low energy structure is 
found115, 122. For every predicted structure, an energy function is defined using Bayesian 
probability theory and in conjunction with Monte Carlo sampling the possible protein 
structures are identified that are energetically stable and compact.  
 
In this study, the hZIP4 model generated by the Rosetta ab initio method was compared with 
mutagenesis studies that probed residues important for transition metal translocation and 
specificity. The model also has a similarity to the central transition metal coordination site of 
the Znt exporter, YiiP37, 123. Comparison of these structures suggests that the Znt and ZIP 
families may share a common zinc coordination geometry.  
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3.2 Materials and Methods 
3.2.1 Reagents 
The radio-isotopes 59FeCl3 were purchased from Perkin-Elmer (Waltham, MA). All transition metal 
chloride salts were purchased from Alfa Aesar, Inc. (Ward Hill, MA). Additional chemicals were 
purchased from Sigma-Aldrich Corp. (St. Louis, MO) unless otherwise indicated. 
 
3.2.2 Expression of hZIP4 in Xenopus laevis oocytes  
Preparation of plasmid constructs and mRNA were performed as previously described in Chapter 
2. Site-directed mutagenesis was performed using QuikChange according to the manufacturer’s 
instruction (Agilent Technologies). Following mutagenesis, the entire gene was sequenced using a 
commercial service (Eton Bioscience Inc.). mRNA was prepared for each mutant and was used to 
express hZIP4 protein in oocytes as described in chapter 2.  
 
3.2.3 Radio-isotope uptake assay 
Radio-isotope uptake assays were performed as described in chapter 2. To identify the zinc 
competing divalent metal, we performed competition experiments similar to WT hZIP4 (see 
Chapter 2) by incubating mutant hZIP4 protein expressing oocytes with 3 µM 65ZnCl2 and 600 µM 
of various transition metals similar to WT hZIP4 competition experiments. Similar to WT hZIP4 
protein, we studied the transport kinetics for each of the mutated hZIP4 protein using the zinc radio-
isotope uptake assay as described in chapter 2. To study the iron uptake assays, we first incubated 
59FeCl3 with 100 fold excess of ascorbic acid to reduce iron to Fe2+. We performed iron uptake 
assay by incubating hZIP4 protein expressing oocytes with 5uM and 10µM of radio-isotope iron 
for 1 hour in reducing condition.  
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3.2.4 Detection of hZIP4 surface expression in oocytes 
hZIP4 surface expression was detected using EZ-Link Sulfo-NHS-SS-Biotin and Biotinylation Kit 
(Thermo Scientific Co.) according to the manufacturer’s instructions. In brief, 35 oocytes 72 hours 
post-injection were washed three times with ice-cold PBS (0.1 M sodium phosphate, 0.15 M NaCl, 
pH 7.2) before incubating them with 2 ml of biotinylation buffer. Sulfo-NHS-SS-Biotin was 
dissolved in PBS to a final concentration of 0.11 mg/ml and oocytes were incubated with 
biotinylation buffer for 90 minutes at 4˚ C with gentle shaking. The reaction was stopped upon 
addition of 200 µl of quenching solution. Biotin-labelled oocytes were washed 4 times with TBS 
(0.025 M Tris, 0.15 M NaCl, pH 7.2). Finally, oocytes were re-suspended in 500 µl of solubilization 
buffer [TBS buffer containing 1 % (w/v) n-dodecyl-beta D-maltoside (DDM) and 1 mM 
phenylmethanesulfonyl fluoride (PMSF)]. Oocytes were homogenized by passing them through a 
25 gauge needle. The lysate was centrifuged at 14000g for 20 minutes at 4˚C. The supernatant was 
collected into microcentrifuge tubes. The pellet was re-suspended in solubilization buffer and 
centrifuged at 14000g for 20 minutes at 4˚C. The supernatants were mixed and incubated with 50 
µl of NeutrAvidin resin at room temperature for 60 min with gentle shaking. The resin was washed 
four times with solubilization buffer. Finally, biotinylated proteins were eluted by boiling resin 
with Laemli buffer for 20 minutes. The eluted biotinylated proteins were separated on SDS-PAGE. 
hZIP4 was detected by Western blot with a rabbit polyclonal antibody raised against the N-terminus 
of hZIP4 (Aviva System Biology Corp.). 
 
3.2.5 Computational modelling of the hZIP4 protein (In collaboration with the David 
Baker lab, University of Washington and Howard Hughes Medical Institute) 
3.2.5.1 Prediction of contact residues in hZIP4 protein  
In this experiment, the input sequence of hZIP4 was trimmed to only include the following residues: 
328-427,487-642.  This trimmed sequence excludes the extracellular N-terminal domain and the 
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only significant intracellular domain between TM3 and TM4. Both of these domains have 
substantial variation between species. A multiple sequence alignment was generated using HMM-
HMM Based Lightning-fast Iterative sequence Search (HHblits)124 with the following options: -n 
8 -e 1E-20 -maxfilt ∞ -neffmax 20 -nodiff -realign_max ∞. HHblits is a statistical model that uses 
HMM to generate an MSA. It has been proposed that when MSA generated using the HHblits 
model, it has higher sensitivity and accuracy that increases the accuracy of co-evolution based 
protein structure prediction. The resulting alignment was then filtered to exclude any sequence that 
did not cover at least 50 percent of the query and to reduce the sequence redundancy to 90 percent. 
The MSA data generated using HHblits was run with GREMLIN default parameters.  
 
3.2.5.2 Rosetta Membrane ab initio modeling for hZIP4  
In this experiment, the standard Rosetta ab initio was used to model the three-dimensional structure 
of hZIP4 trimmed to only include residues 328-648. The default Rosetta energy function was 
modified to enable membrane specific terms with the following weights: fa_sol - 0.0, fa_mbenv - 
0.3, fa_mbsolv - 0.35 and Menv_smooth - 0.5125, 126. Transmembrane spans (residues 2-23, 33-53, 
74-95, 167-191, 197-222, 228-252, 259-282, and 290-314) were defined using the consensus output 
of the MEta Sever for Sequence Analysis (MESSA server )127. MESSA server is a computational 
sequence analytical tool that can be used to predict the local sequence properties, spatial structure 
and function together. To reduce the sampling space in hZIP4 model prediction, sigmoidal 
restraints that modified the energy function were introduced. The shape of the sigmoid is defined 
using a distance cutoff, the slope, the intercept and the strength of the weight parameter using an 
equation described below.  
sigmoid(d) = weight1 + exp(−slope(d− cutoff)) + intercept 
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To favor sampling of topologies consistent with GREMLIN predictions, sigmoidal distance 
restraints (Figure 14) were introduced between residue-pairs predicted to be in contact by 
GREMLIN (Figure 15). When used in the centroid stage of Rosetta, these restraints were 
introduced between carbon-beta atoms (carbon-alpha in the case of glycine), at amino acid pair 
specific Cβ-Cβ cutoff and slopes, as described in SI Table III  within116; in the full-atom stage, 
these were replaced with ambiguous distance restraints between side-chain heavy atoms (cutoff of 
5.5 and slope of 4)128. The relative weight of each restraint was based on the GREMLIN score. The 
total atom-pair restraint score was scaled to be roughly ½ the total Rosetta score.  
 
In addition to these restraints, additional strong repulsive distance restraints (weight -100, cutoff 
35, slope 2 and intercept of 100) were added between extracellular regions (defined by residues 
329,391,522,582,648) and intracellular regions (defined by residues 353,425,490,553,615), and 
strong attractive restraints (weight 100, cutoff 35, slope 2 and intercept of 0) within intracellular 
regions and extracellular regions, effectively constructing a membrane-like sampling space (Figure 
14). These restraints were introduced between pairs of Cα atoms.  
 
The top 1010 models ranked by distance restraints score, with z-score ≥2 (Figure 16) were clustered 
based on structural similarity as calculated by TMscore129 after excluding the regions (positions 
428-486 and 643-648). Clusters were defined as connected components of a network, where each 
edge is between models with TMscore ≥0.7. The selected model was then further energy minimized 
with Rosetta to remove clashes, while respecting structural symmetry and GREMLIN restraints130.  
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Figure 14. Sigmoidal distance restraint function. “d” is the distance between given distance 
evaluated 
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Figure 15. Contact map showing top co-evolved TM residues in hZIP4. A) Contact map, left to 
right, top to bottom (N to C-terminus) showing the top 384 co-evolving residues between 
transmembrane helices represented as a contact map. The darker and larger the blue dots, the higher 
strength in covariance. B) Table of inter-helical residue pairs, within the top 64 predictions. The 
matching labels are shown in bottom-left portion of the contact map (A) 
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Figure 16. Distribution of GREMLIN restraint scores for Rosetta Ab initio models. Models above 
the red line (with z-score ≥ 2) were selected for the clustering analysis. The selected model is the 
refined model from cluster A (See Figure 21A). The Ab initio models closer to the selected model 
tend to have a higher GREMLIN restraint score. 
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3.2.6 Oligomeric state of hZIP4 
Adapting the protocol from Dürr et al, 50 oocytes were added to breaking buffer [20 mM HEPES, 
pH 7.4, 150 mM NaCl and 1 mM phenylmethanesulfonyl fluoride (PMSF)] and passed through a 
25 gauge needle followed by one minute low speed centrifugation (100g and 4˚ C)131. The 
supernatant was collected in a separate micro-centrifuge tube and centrifuged (1 minute at 100g 
and 4˚ C). The procedure was repeated until no pellet was observed upon centrifugation. The 
supernatant was then spun down at 14000g for 30 minutes at 4˚ C. The membrane pellet was re-
suspended in solubilizing buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 1% w/v DDM and 1 mM 
PMSF) and incubated at room temperature for 5 minutes. The insoluble fraction was separated by 
high speed centrifugation (14000g for 30 minutes at 4˚ C). The supernatant was added into Laemmli 
buffer in the absence of reducing agent. The solubilized total membrane proteins were separated 
on SDS-PAGE. The Western blot was developed using rabbit polyclonal antibody raised against 
N-terminus of hZIP4 (Aviva System Biology Corp.). 
 
3.2.7 Glycosylation of hZIP4 
Fifty oocytes were either injected with either 500 ng of hZIP4 mRNA or co-injected with 500 ng 
of hZIP4 mRNA and 10 ng of tunicamycin. The oocytes were incubated in ORI+ buffer for three 
days. Post hZIP4 expression, the hZIP4 surface expression was measured using the protocol 
described earlier in 3.2.4. 
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3.3 Results 
3.3.1 The effect of histidine to alanine mutations on hZIP4 zinc transport 
Based on our earlier finding that covalent modification of histidine, but not cysteine residues, 
dramatically decreases zinc translocation mediated by hZIP4, we designed experiments to examine 
the functional role of each histidine residue within the transmembrane domains of this protein for 
transition metal translocation. hZIP4 encodes six transmembrane histidine residues: 379 (TM2), 
507 (TM4), 536, 540 and 550 (TM5) as well as 624 (TM8). We individually replaced each TM 
histidine residue with alanine. Zinc transport kinetics were determined for each of the mutant 
transporters using our established uptake assay. Previously, we have demonstrated that the wild 
type hZIP4 has two distinct Km’s: 76 ± 5 nM and 1.4 ± 0.3 µM. Alanine substitution at the TM 
histidine residues altered the nM Km for three mutant proteins: H379A, H507A and H536A (Table 
5). In addition, alanine replacement abolished the µM Km for one mutant protein (H379A). Equally, 
no zinc translocation was observed for the H624A mutant (data not shown).  
 
Representative data for one of these mutants (H540A) is shown in Figure 17. Furthermore, to 
directly compare Vmax between the wild type and mutant constructs, oocytes expressing each 
construct were incubated with 3 µM 65ZnCl2. When normalizing the data to surface expression, the 
Vmax was significantly lower for the H379A, H507A, H536A, H540A and H624Q mutants (but not 
H550A) when compared to the WT protein (Figure 18).  Analysis of transport data for some 
constructs revealed Hill coefficients with non-Michaelis-Menten behavior (Table 5). This could be 
due to one or more factors including a flip-flop model where a dimeric transporter has reciprocal 
conformations, a ping pong mechanism or random substrate binding if more than one zinc  atom is 
transported per transport cycle132, 133. It was also determined that zinc transport was roughly linear 
over the time of the assay (60 min) upon addition of 21.75 µM 65ZnCl2 (Figure 19). We have 
previously demonstrated that under these conditions, 65Zn2+ uptake is linear for WT-hZIP4 over 2 
hours as shown in Chapter 2.  
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Figure 17. The Zn2+ transport parameters, Km and Vmax, of the H540A mutant. The kinetic 
parameters for hZIP4 mutant was elucidated at low (A) and high (B) concentrations of zinc by 
measuring amount of 65Zn2+ uptake into oocytes injected with hZIP4-Strep (with H540A mutant) 
mRNA over one hour in assay buffer which contained varying amounts of 65ZnCl2.  The data was 
fit to the Michaelis-Menten equation described in the text; data originated from 5-8 oocytes; values 
are means ± SEM. 
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Figure 18. Relative velocity of WT hZIP4 and mutant transporters. (A) Oocytes were injected with 
25 ng of WT hZIP4 or mutant hZIP4 mRNA. After 3 days of incubation at 16˚ C, oocytes were 
subjected to radioisotope uptake experiment.  Oocytes were incubated with 3 µM 65Zn2+ and zinc 
uptake was measured after 60 min. Transport data was normalized to surface expressed protein 
(Figure 8B). * indicates a statistically significant difference in zinc uptake between mutant hZIP4 
and WT after uptake was normalized to level of protein surface expression (p < 0.05). (B) Western 
blot of surface expressed WT and mutant hZIP4 proteins isolated as described in Materials and 
Methods. The relative expression of hZIP4 was quantified using Quantity One software (Bio-Rad 
Laboratories, Inc.). (C) Western blot of biotinylated WT and mutant hZIP4 proteins isolated as 
described in Materials and Methods. 
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Table 5. Zinc Transport Kinetic Parameters for WT and mutant hZIP4 transporters. Kinetic 
parameters were determined by measuring amount of zinc taken up with hZIP4-Strep mRNA as 
described in the methods and materials. The data were fit to the Michealis-Menten equation as 
described in the materials and methods. Data originated from five to eleven oocytes, values are 
means ± SEM. Km values statistically different (p < 0.05) from wt hZIP4 are in bold. No statistical 
tests were performed on Vmax as assays were performed on separate days and surface expression 
was variable between days. N.D. = none detected. 
 
 
 
 
 
 
 
 Vmax(1) 
(pmol/oocyte/
hour) 
n1 Km1 (nM) Vmax(2) 
(pmol/oocyte/
hour) 
n2 Km2 
(µM) 
WT 1.4 ± 0.1 3.6 ± 0.6 76 ± 5 13 ± 1 1.2 ± 0.3 1.4 ± 0.3 
H379A 0.8 + 0.01 4.2 + 0.7 370 + 10 N.D. N.D. N.D. 
H507A 0.6 + 0.1 6.1 + 2.9 220 + 20 2.3 + 0.2 0.9 + 0.1 1.8 + 0.4 
H536A 0.7 + 0.1 2.4 + 1.1 210 + 50 3.1 + 0.3 1.3 + 0.3 1.9 + 0.5 
H540A 0.9 + 0.1 2.1 + 0.8 70 + 20 6.5 + 0.9 1.2 + 0.4 1.4 + 0.6 
H550A 0.4 + 0.1 1.2 + 0.7 60 + 30 0.8 + 0.01 1.8 + 0.3 0.5 + 0.1 
H624A N.D. N.D. N.D. N.D. N.D. N.D. 
H624Q 1.1 + 0.1 1.8 + 0.9 60 + 17 3.3 + 0.1 2.9 + 0.9 0.8 + 0.1 
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Figure 19. Time course of zinc uptake for mutant constructs. Oocytes, injected with 25 ng of hZIP4 
mutant constructs were incubated with 21.75 µM 65ZnCl2. The assay was quenched every 30 min 
up to 120 min, and data originated from five to eight oocytes; values are means ± SEM. Fitting the 
data to the equation to a standard linear equation (y = mx + b) resulted in the following R2 values: 
H379A (0.9685), H507A (0.9683), H536A (0.9824), H540A (0.9816), H550A (0.9949) and H624Q 
(0.9493). 
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3.3.2 Histidine 624 is essential for biometal translocation 
Hydropathy analysis predicts that H624 is located on the cytoplasmic end of TM8 and is not 
conserved among ZIP family proteins. Considering that ZIP member proteins which function as 
iron transporters (ZIP8 and ZIP14) encode glutamine at this position, we replaced histidine with 
glutamine at this position to further elucidate the role of this residue in transition metal permeation. 
The H624Q mutation retained zinc translocation function, while having a tighter µM Km (Table 5). 
To further explore the functional role of H624 in biometal translocation, we performed a 
competition experiment where 200 fold excess of various divalent cations were added to our uptake 
assay in the presence of 3 µM 65Zn2+. Previously, we have shown that in the wild type transporter, 
zinc transport is inhibited by 200-fold excess Cu2+, Ni2+, and Zn2+. In addition, Zn2+, Cu2+ and Ni2+ 
are transported by hZIP4. In contrast to the wild type transporter, 65Zn2+ transport was significantly 
inhibited by Cu2+, Ba2+, Co2+, Fe2+, Mn2+, Ni2+ and Zn2+ for the H624Q mutant transporter (Figure 
20). 
 
3.3.3 Residues contribute to cation selectivity of ZIP transporters  
To explore the role of the transmembrane histidine residues in cation specificity for hZIP4, we 
examined the relative velocity of Fe2+ and Zn2+ uptake for wt and each mutant construct (Table 6). 
The rationale for this experiment was the observation that zinc transport was inhibited for the 
H624Q mutant construct by high levels of iron in our competition assay. Therefore, we 
hypothesized that the H624Q mutant hZIP4 transporter would translocate Fe2+. Analysis of our 
experiments demonstrated that wild type hZIP4 transports Fe2+, but that the H624Q mutant 
transporter is a poor iron transporter. Equally, replacement of three histidine residues with alanine 
significantly altered the velocity ratio of Fe2+ and Zn2+ transport (H379A, H507A and H536A) 
(Table 6).  
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Figure 20. Competition of 65Zn2+ uptake in H624Q expressing oocytes with a series of divalent 
cations.  To determine which divalent cations inhibited hZIP4-mediated 65Zn2+ uptake, oocytes 
expressing hZIP4 were pre-incubated in 600 µM cold ZnCl2, BaCl2, CdCl2, CoCl2, CuCl2, FeCl2, 
MgCl2, MnCl2, or NiCl2 in the uptake assay buffer.  The uptake assay was initiated by adding 3.0 
µM 65ZnCl2.  The assay was quenched after one hour as described in the Materials and Methods 
section; data were normalized to the amount of 65Zn2+ uptake in the absence of competing cation; 
data originated from 14-17 oocytes; values are means ± SEM. Data marked with * represents 
statistically significant different from wt (p<0.05). 
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Table 6. Relative Specificity for Zn2+ and Fe2+ for WT and mutant hZIP4 transporters. A final 
concentration of 5 µM of indicated metal was applied to oocytes expressing wt or mutant hZIP4 
protein. Data originated from eight to eleven oocytes, values are means ± SEM.  Zn2+/Fe2+ uptake 
values for mutant proteins statistically different (p > 0.05) from wt hZIP4 are in bold. Similar results 
were obtained upon application of 10 µM of indicated metal. N.D. = none detected. 
 
 
 
 
 
 
 
 
 
 Zn2+ Uptake 
(pmol/oocyte/hour) 
Fe2+ Uptake 
(pmol/oocyte/hour) 
Zn2+/Fe2+ Uptake 
WT 2.2 + 0.2 0.61 + 0.07 3.6 + 0.7 
H379A 1.3 + 0.3 0.64 + 0.04 2.0 + 0.6 
H507A 2.7 + 0.3 0.38 + 0.07 7 + 2 
H536A 1.4 + 0.2 2.1 + 0.1 0.7 +  0.1 
H540A 3.5 + 0.5 0.65 + 0.04 5 + 3 
H550A 1.9 + 0.2 0.46 + 0.07 4.1 + 0.8 
H624A N.D. 0.24 + 0.05 undefined 
H624Q 2.4 + 0.2 0.26 + 0.06 9 + 2 
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3.3.4 Residue-residue contacts predicted from co-evolution (in collaboration with the David 
Baker lab) 
We built a model of this protein using predicted contact residues and the Rosetta Membrane models 
and compared the results with non-redundant PDB membrane protein structures116, 134, 135. 
Membrane structures have been modeled using contact predictions based on co- evolutionary 
patterns in large MSAs of homologous proteins136, 137. To see if such an analysis was possible for 
hZIP4, we constructed an alignment over the conserved transmembrane region by querying the 
UniProt database with HHblits124, 138. The resulting non-redundant alignment contained 1731 
homologous sequences, 6.8 sequences per length of 255, which is more than the minimum 
sequences (5 sequences per length) required to predict residue pairs in contact in the three 
dimensional structure of hZIP4 using GREMLIN, a co-evolution based contact prediction approach 
that is more accurate than other extant approaches116. These predictions were then used as distance 
restraints in the Rosetta ab initio protocol along with other membrane-specific terms to generate 
over 100,000 structural models of hZIP4 using a distributed computing network, Rosetta@home. 
Of these, the top 1010 models based on restraint score were extracted and the contact map was 
generated for each predicted protein. An analysis of contact maps of selected co-evolution based 
top models suggested that they formed three large clusters (Figure 21) of which one cluster agreed 
with GREMLIN predictions and formed physically realistic structures.  
 
Despite this extensive sampling, we observed one set of predicted contacts that were consistently 
not made by the structural models (Figure 21A). Further inspection revealed that it was physically 
impossible to make all these contacts in regions between TM2-3 and TM7-8, without breaking 
contacts between other helices in a monomeric state. The top 384 (1.5 x length of query) co-
evolving pairs of residues that were at least three residues apart (Figure 15) in the protein sequence 
were then selected to be used in subsequent structural modeling in Rosetta. Using these top co-
evolving pairs, an oligomeric interface could be readily made (Figure 22B-C and 23). Notable for  
71 
 
Figure 21. Contact maps showing contacts made within each cluster, below that are cartoons of 
the top three models colored blue to red (n to c terminus) for each cluster. The intensity of the blue 
(in the contact map) is indicative of the percent of models within the cluster that make those 
contacts. Ranging from light blue: 10% to blue 100%. Red boxes indicate helices predicted to be 
in contact but are not in the given cluster. A) Cluster A makes contacts between all the top co-
evolving helices, but there is a disagreement between models in the regions boxed in green. Further 
analysis reveals that variation within cluster A is explained within the context of dimer helix 
swapping (Figure 23). Both clusters B and C, have missing helical contacts in regions with strong 
co-evolution signal. Additionally, they both expose histidines into the membrane, which is highly 
improbable for membrane proteins. 
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Figure 22. Models of hZIP4 were generated using Rosetta structure prediction guided by 
coevolution based contacts, as described in the text. A) Ribbon diagram of the monomer structure 
colored blue to red (n to c terminus), shows the predicted location of the trans membrane histidines 
in white. For clarity, the loop between residues 428 to 486 is omitted. B) Consistency of coevolution 
predicted contacts with hZIP4 structural model.  Black dots, predicted contacts; grey, contacts in 
the Rosetta model monomer; red, contacts across dimer interface. The top coevolving residues are 
made within the context of the dimer. C) Dimer view of the Rosetta structure model of hZIP4. The 
top 25 contacts are shown as yellow dashes. The highlighted regions (red and dark blue) indicate 
the conserved LIV-1 sequence in the fourth transmembrane helix. 
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these results is that each of the variants in cluster within Figure 21A can make the dimer interface 
as shown in Figure 23. Equally, these models have histidine residues lining the transmembrane core 
forming a potential permeating pathway (Figure 22A). 
 
3.3.5 Structural Alignment of hZIP4 with membrane protein structures (in collaboration 
with the David Baker lab) 
To examine whether the model of hZIP4 was similar in structure to more distal membrane proteins, 
we performed structural alignments between the model and all known crystal structures of 
membrane proteins, in the Protein Data Bank of Transmembrane Proteins (date: 2013-12-27), using 
TMalign134, 135, 139. The hZIP4 dimeric model is closest in structure to MFS transporters (Figure 24). 
The highest ranked MFS transporter is PiPT, a eukaryotic phosphate transporter (Figure 25). The 
MFS and CDF proteins are separate families within the SLC group of proteins140. PiPT encodes 
twelve TM domains in a twofold axis of symmetry where phosphate translocation occurs at the two 
fold axis. 
 
3.3.6 Oligomeric State of hZIP4 
TM7 from each monomeric unit are adjacent helices in each of the top ranked models (Figure 23). 
Therefore, to elucidate whether the oligomeric state of hZIP4 could be disrupted using our model 
as a template, we replaced residues within TM7 with tryptophan. Oocytes were injected with wt or 
mutant hZIP4 mRNA. Total membrane proteins were isolated after 72 hours. Following Western 
blot analysis, it was observed that wt hZIP4 is comprised of both monomeric and dimeric 
complexes (Figure 26A). Replacement of some, but not all, residues along TM7 with tryptophan 
resulted in mutant proteins which favor a monomeric state. In our Western blot analysis, we 
observed three distinct bands, where the higher band indicates dimer and the lower  
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Figure 23. Variations within cluster A are consistent within context of a dimer. When we examine 
variation within cluster A, we find that the models are capable of making the remainder of the top 
co-evolving residues in the context of a dimer. For example, if we reconnect the loop regions 
between helices 2 and 3, swapping helix 3 between the homo-dimer (A->B), this preserves all 
predicted helical contacts. Another example would be to reconnect the loop between helices 7 and 
8, swapping helix 8 (A->C), or a combination of both (A->D). These swaps are represented in the 
variation of the top cluster (Figure 21A). 
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Figure 24. Structural homology of hZIP4 dimer to other membrane proteins. The red filled circles 
are MFS proteins. EmrE and YiiP are the efflux multidrug transporter and Znt zinc exporter, 
respectively. 
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Figure 25. Comparison of hZIP4 model and MFS Transporter structure. A) Similarity of the 
Rosetta model of hZIP4 with the structure of the Major Facilitator Superfamily (MFS) Transporter 
(PDB: 4j05). Loop regions and helices 1 and 6 of hZIP4 are not shown for clarity. TM-score 0.66 
(3.53 RMSD over aligned region). B) Alignment of trans-membrane helices in sequential space. 
The matching colors of hZIP4 and MFS indicate structural alignment. The grey regions did not 
align and were not shown in (A). 
 
 
 
 
 
 
77 
 
Figure 26. Western blot analysis of tryptophan scanning mutagenesis studies along TM7. A) 
Residues replaced with tryptophan are indicated above blot. Arrows represent (from top to bottom) 
dimer, glycosylated monomer-1 and nonglycosylated monomer-2. B) WT hZIP4 injected oocytes, 
when co-injected with tunicamycin showed a lower molecular weight of surface expressed hZIP4 
suggesting that glycosylation may not be vital to membrane localization.  
 
                          A 
 
 
 
                          
                         B 
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bands indicate two different populations of monomer. Between the two different monomer 
populations, it is possible that one (monomer-1) is glycosylated and the other (monomer-2) is either 
non-glycosylated or a differently glycosylated form. Additionally, when oocytes were co-injected 
with wt-hZIP4 mRNA and tunicamycin, the resulting surface expressed hZIP4 protein had lower 
molecular weight than when injected with wt-hZIP4 mRNA alone. The result of our tunicamycin 
injected hZIP4 protein surface expression suggests that glycosylation may not be important for 
hZIP4 membrane localization. However, we have not measured the Zn2+ transport in non-
glycosylated hZIP4 protein expressing oocytes. Others have observed a similar pattern of two 
monomeric states97. Notably, the L602W mutation resulted in nearly all of hZIP4 in the monomer-
1 state. Equally the D604W mutation greatly diminished the dimer population, however overall 
distribution of monomers is not affected for this mutant protein. Finally, the M605W mutation did 
not affect the relative distribution of hZIP4 oligomeric states. 
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3.4 Discussion 
In this study, we designed experiments to investigate the zinc permeation pathway in hZIP4 protein. 
Our earlier experiments suggested that extracellular water accessible histidine residues are 
important for hZIP4 mediated zinc transport. To further investigate the role of TM histidine 
residues, we mutated each of the six histidine residues predicted based on hydropathy analysis to 
alanine. Our zinc uptake assay for each of the alanine mutants showed that the mutation affects 
either Km (Table 5) or the rate of transport (Figure 18), which suggests that these residues are either 
part of the zinc permeation pathway or are important for maintaining structural integrity of the 
permeation pathway. It is worth noting that our Vmax results have certain caveats. For example, we 
did not measure the labelling efficiencies of the biotinylating reagents, optimize avidin bead/total 
membrane protein ratio or determine the avidin bead bed volume to bind all the labelled protein 141. 
We understand that the interpretation of our Vmax results may change, if they were to be reanalyzed 
with more detailed surface biotinylation experimental conditions. It is plausible that overexpression 
of hZIP4 may result in protein misfolding which may lead to distinct protein populations with 
altered transport kinetics or metal specificity. While Km or normalized Vmax values between 
differing expression systems may differ, it is likely that trends, such as mutations which result in 
higher/lower affinities or changes in normalized Vmax, will be consistent between overexpression 
systems. Furthermore, considering that both micromolar and nanomolar Km values have been 
observed upon heterologous expression in mammalian cells as well as X. laevis oocytes, this 
suggests that either both affinities are present in vivo or that overexpression in both cell types gives 
equivalent artifacts64, 74. Therefore, analysis of hZIP4 transport experiments performed in X. laevis 
oocytes is a viable and valuable method to examine transport properties for this class of proteins. 
Equally, the non-Michaelis-Menten Hill coefficients could be due to one or more factors including 
a flip-flop model where a dimeric transporter has reciprocal conformations, a ping pong mechanism 
or random substrate binding if more than one zinc molecule is transported per transport cycle.  
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We were surprised to learn that the mutation of histidine to alanine at position 624 resulted in an 
inactive protein even though H624 is the least conserved residue amongst human LIV-1 subfamily 
proteins. The loss of activity in H624A mutant could be a result of no protein expressing in plasma 
membrane. However, our biotin labelling experiment showed that H624A is expressed (Figure 
18C) in the plasma membrane. Therefore, we believe that the 624 residue is important for 
maintaining the structural integrity of the hZIP4 protein. Additionally, mutation of H624 to the 
second most conserved glutamine residue in human LIV-1 subfamily proteins resulted in rescuing 
of the zinc transport activity in hZIP4 protein although with a different pattern of substrate 
specificity (Figure 20) than WT hZIP4 protein. 
 
Seeking to further explain our results and to explore the zinc permeation pathway in hZIP4 protein, 
we decided to use the GREMLIN contact prediction using the pseudo likelihood approach with 
Rosetta membrane protein structure prediction method to model the transmembrane (TM) domains 
of hZIP4. The 327 residue N-terminal domain was excluded because there were not enough 
homologous sequences to perform a coevolution analysis. The 76 residue cytosolic domain between 
TM3 and TM4 was included in the structural modeling, but was removed during clustering and 
analysis, since it did not converge to a low number of structures. The eight transmembrane domains 
encode a core structure comprised of TMs 2, 4, 5, and 7 with additional transmembrane domains 
(TMs 1, 3, 6 and 8) peripheral to this core structure. Mechanistically, the hZIP4 model encodes a 
central transition metal coordination site similar to the YiiP crystal structure (Figure 27). 
Mutagenesis of residues within the YiiP metal coordination site alters the transition metal 
specificity of YiiP142. Among ZIP member proteins, residues which comprise this putative metal 
coordination site are variable and amino acid differences within this coordination site likely 
contribute to a differing cation specificity among ZIP transporters143. An unresolved question is 
elucidating the permeation pathway or pathways which comprise the nM and µM Km’s. Inspection  
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Figure 27. Comparison of hZIP4 with YIIP. A) Expanded view of putative YiiP and hZIP4 
transition metal coordination sites. B) Weblogo showing the conservation at each position. 
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of our experimental results demonstrate that alanine replacement of residues H379, H507 and 
H536, residues which form a cation coordination site similar to the zinc exporter YiiP, significantly 
alters the nM Km at each residue (Tables 5 and 6). In addition, alanine replacement of H624, which 
is located at a potential exit-point for transition metals is also significantly changed in the nM Km. 
Therefore, our in situ data supports the conclusion that the nM permeation pathway is comprised, 
at least in part, of the transmembrane domains which comprise the pore structure of hZIP4. In 
contrast, the µM Km is altered or abolished upon alanine replacement residues H379, H550 and 
H624. Residues H550 and H624 are located in close proximity at the exit of the putative pore, on 
the intracellular side of hZIP4, while H379 is located at the top of the pore and within the putative 
coordination site. 
 
The results of our computational modeling also suggested that the model structure of the hZIP4 
protein could satisfy the predicted contacts and retain membrane-like topologies (Figure 23) in 
multiple oligomeric states. In our proposed oligomeric structure of the hZIP4 protein, the interface 
for each dimer model is comprised of TMs 3, 4, 7 and 8. It is important to note that while our 
approach can define residue pairs which are co-evolving, co-evolution between residues does not 
always mean contact for all conformational states of the protein. Some contacts may only be made 
in one conformational state, while other contacts may comprise higher order oligomeric assemblies. 
Furthermore, models with a z-score greater than or equal to two were selected for the clustering 
analysis (Figure 16). Published experimental support for the dimeric model is derived from two 
sets of experiments. First, direct analysis of size exclusion HPLC suggested that the oligomeric 
state of ZIPB in detergent micelles was consistent with a dimer144. More recently, it was observed 
that hZIP13 is dimeric following chemical cross-linking57. Analysis of our tryptophan scanning 
mutagenesis experiments suggests that dimer formation can be disrupted upon mutagenesis along 
TM7. 
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Analysis of TM scoring demonstrates that the hZIP4 dimer model retains the same fold as MFS 
proteins. The closest MFS homolog is the twelve transmembrane monomeric eukaryotic phosphate 
transporter, PiPT140. Recently, it has been proposed that MFS transporters evolved either from three 
TM unit rearrangements or a common ancestor without three TM unit rearrangements145-148. While 
analysis of our data provides further insight into the evolutionary relationship between SLC 
proteins, it is important to note that there are caveats to this analysis. First, analysis of our modeling 
experiments identified four possible dimeric interfaces. Some of the lower scoring models have 
slightly lower TM-scores when compared with the PiPT transporter. If the lower scoring models 
prove to be more accurate, then the comparison between the PiPT structure and the hZIP4 model 
should be re-analyzed. Second, the transport pathway for PiPT is along the homologous dimer 
interface of the hZIP4 model. This could suggest a different mechanism of transport for these two 
families of transporters. Alternatively, it could also be true that the proposed three TM unit 
rearrangements described above resulted in proteins with new functionalities which is exhibited in 
hZIP4.  
 
In summary, by employing Rosetta with co-evolution and membrane terms in tandem with 
functional experiments, we have developed the first molecular model for ZIP proteins. This model 
can be used to examine the location of residues which contribute to specificity (H379, H507, H536 
and H624) as well as the velocity of metal transport (H379, H607, H536, H540 and H624). We 
expect that this model will open new avenues and experimental approaches to identify more 
nuanced mechanistic questions such as residues which contribute to transition metal docking within 
the ZIP family of proteins. 
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4. The large intracellular loop of hZIP4 is an intrinsically 
disordered zinc binding domain 
 
 
 
 
 
 
 
 
 
Note: I thank Dr. Timothy L. Stemmler and Stephen P. Dzul for X-ray absorption spectroscopy 
experiments and results. I thank Dr. Elizabeth M. Bafaro for her help with atomic absorption 
spectroscopy. I thank Tuong-Vi Nguyen and Brian Doyon for their contribution during various 
stages of project development.   
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4.1 Introduction 
The total zinc cellular concentration is in the micromolar range7. However, the free cytosolic zinc 
concentration in eukaryotic cells is in the picomolar range7, 11, while the zinc concentration within 
zinc storage granules can be as high as millimolar concentration12. To control the zinc concentration 
in various cellular compartments, cells have evolved to have highly specialized systems. The 
metallothionein and zinc transporter proteins are the most important protein families, which 
regulate zinc concentrations within various cellular compartments. Metallothionein proteins and 
their zinc-binding properties have been studied in great detail32, however such information 
regarding the zinc transport proteins remains elusive. 
 
In the previous chapter, we took advantage of co-evolution data and the Rosetta algorithm to predict 
the hZIP4 membrane domain structure. Our functional studies of mutant hZIP4 proteins using 
X.laevis eggs was also in agreement with the predicted hZIP4 model structure. However, we could 
not converge the cytosolic loop M3M4 into a small number of structures, and therefore the M3M4 
domain was excluded from the clustering and structural analysis. In this study, we used 
bioinformatics analysis and experimental evidence to show that the M3M4 protein domain is a 
disordered region of the hZIP4 protein. Recently, intrinsically disordered proteins (IDPs) and 
intrinsically disordered protein regions (IDPRs) have become recognized as having important 
biological functions in cell signaling, regulation and control, although they lack secondary and 
tertiary structural elements149. IDPRs are estimated to be present in over 35% of human proteins150. 
In the case of membrane proteins, a survey of the Protein Data Bank identified disordered regions, 
as determined by missing electron density in crystal structures, in more than half of deposited 
membrane protein structures151. Moreover, an analysis of human plasma membrane proteins found 
that over 40% contained disordered regions of more than 30 amino acids in length, and these 
disordered regions were three times more likely to occur on the cytoplasmic side than on the 
extracellular side of the membrane152. Inside cells, IDPs and IDPRs participate in molecular 
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recognition functions by binding to target molecules such as nucleic acid, proteins or small 
ligands153. Among their molecular recognition functions, IDPs and IDPRs act as scavengers for 
ions or small molecules and provide display sites for post-translational modifications such as 
phosphorylation and ubiquitination153. 
 
Functional studies have shown that the zinc transport proteins regulate cytosolic zinc 
concentrations by importing or exporting zinc to and from cellular compartments 154. Cells also 
regulate cytosolic zinc concentrations by altering the expression levels of zinc transport proteins. 
For example, the expression of zinc exporting proteins such as ZnT1, ZnT2, ZnT4, ZnT5 and ZnT6 
have been observed to be down-regulated under a zinc deficient diet, whereas the diet supplemented 
with an excess of zinc resulted in up-regulation of ZnT protein expression154. In conjunction with 
the up-regulation of ZnT proteins, an excess of dietary zinc was shown to down-regulate the zinc 
importer ZIP3 protein expression154. Similarly, ZIP4 and ZIP10 proteins are down-regulated in zinc 
replete conditions154. More detailed studies on the hZIP4 protein has revealed that at high cytosolic 
Zn2+ concentrations, ZIP4 undergoes Zn2+-dependent endocytosis, thereby reducing ZIP4 levels in 
the plasma membrane97. At even higher zinc concentrations, hZIP4 is ubiquitinated, presumably at 
a highly conserved lysine residue within a large intracellular loop between transmembrane domains 
III and IV (M3M4) and is further subjected to proteasomal degradation96. Furthermore, zinc 
dependent ubiquitination and degradation requires the presence of a histidine-rich domain located 
on the large cytosolic loop. Taken together, these observations led to the hypothesis that the M3M4 
domain acts as a zinc sensor to regulate hZIP4 expression in the plasma membrane96. In this study, 
we describe the metal binding properties of the significant intracellular loop located between 
transmembrane domains III and IV (M3M4) of hZIP4. We provide the first direct evidence that 
this domain coordinates two Zn2+ ions. Moreover, Zn2+ coordination occurs in a sequential manner 
with the first Zn2+ binding with nanomolar affinity to a CysHis3 site and the second Zn2+ binding 
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with a lower affinity to a His4 site. Finally, we show that the intracellular M3M4 loop is an 
intrinsically disordered region. 
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4.2 Materials and Methods 
4.2.1 Materials 
D-Desthiobiotin and Strep-Tactin Superflow resin were purchased from IBA Life Sciences. Zinc 
chloride, isopropyl-β-D-thiogalactopyranoside (IPTG), ethylenediaminetetraacetic acid (EDTA), 
ethylene glycol tetraacetic acid (EGTA) and N-ethylmaleimide (NEM) were purchased from 
Sigma-Aldrich. Glycerol, tris(2-chloroethyl) phosphate (TCEP), 4-(2-Hydroxyethyl)piperazine-1-
ethanesulfonic acid (HEPES), diethyl pyrocarbonate (DEPC), and N,N′-dicyclohexyl carbodiimide 
(DCCD) were purchased from Amresco. 4-morpholinepropanesulfonic acid (MOPS) was 
purchased from BDH Chemicals. 
 
4.2.2 Bioinformatics 
Disorder predictions were performed using FoldIndex (http://bip.weizmann.ac.il/fldbin/findex)155. 
The FoldIndex is an algorithm that predicts whether the given protein sequence is disordered based 
on the average hydrophobicity of the residues and net charge of the sequence155.   
 
4.2.3 Molecular cloning 
The gene sequence corresponding to the predicted intracellular domain (M3M4) between residues 
424 and 498 of the hZIP4 protein was amplified by PCR from the hZIP4 gene. The resulting PCR 
product was cloned into the overexpression vector pPR-IBA1 (IBA Life Sciences) to generate 
pPRIBA-M3M4 using the unique restrictions sites KpnI and NcoI. The pPR-IBA1 vector 
introduced a C-terminal Strep tag for affinity purification. Site-directed mutagenesis to generate 
single cysteine or histidine mutant proteins was performed according to the manufacturer’s 
instructions (Agilent Technologies). Gene synthesis (GenScript) was used to generate triple 
mutants. All plasmid constructs were verified by DNA sequencing. 
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4.2.4 Protein expression, purification and labeling 
The pPRIBA-M3M4 plasmid was transformed into E. coli BL21(DE3) pLysS cells carrying the 
pSJS1240 plasmid coding for rare tRNAs156. Transformed E. coli cells were grown at 37˚ C in TB 
medium (0.012% (w/v) trypton, 0.024% (w/v) yeast extract, 0.004% (v/v) glycerol, 1.7M potassium 
dihyrogen phosphate and 0.72M potassium hydrogen phosphate) containing 100 µg/ml ampicillin, 
34 µg/ml chloramphenicol and 50 µg/ml spectinomycin. Protein expression was induced by adding 
100 µM IPTG to a culture of OD600 0.6-0.8, and expression was carried out at 18˚ C for 20 hours. 
The cells were harvested and washed with wash buffer (20 mM HEPES, 150 mM NaCl, pH 8). The 
protein was purified using a boiling lysis method previously reported for the purification of IDPs157, 
158. The cell pellet from a 1 L culture was resuspended in 20 ml wash buffer containing 2 mM 
EDTA and 1 mM dithiothreitol. The cells were lysed by boiling for 20 minutes, followed by 
incubation in an ice-salt bath for 5 min. All remaining purification steps were performed at 4˚ C. 
The lysed cells were sonicated for 30 s to shear the DNA and the cell lysate was clarified by 
ultracentrifugation for 30 minutes at 100,000 x g. The resulting soluble fraction was loaded onto a 
Strep-Tactin Superflow (IBA Life Sciences) gravity column. The column was washed first with 
wash buffer containing 0.2 mM EDTA and 0.1 mM TCEP, followed by buffer exchange with 
chelex-100 treated elution buffer (20 mM HEPES, 150 mM NaCl, 20% (v/v) glycerol, 0.1 mM 
TCEP, pH 7). The protein was eluted in chelex-100 treated elution buffer containing 2.5 mM D-
desthiobiotin. Protein was quantified using the Reducing Agent Compatible Pierce™ Microplate 
BCA Protein Assay Kit (Thermo Scientific Co.). For labeling, the purified protein was incubated 
with 0.5 mM DCCD, 10 mM DEPC, or 1 mM NEM for 30 minutes at 4˚ C followed by extensive 
dialysis against chelex-100 treated elution buffer.  
 
4.2.5 Circular dichroism spectroscopy 
All CD spectra were recorded using a Jasco J-1500 CD spectrometer in 1-mm quartz cuvettes. 
Protein samples were prepared in 20 mM TRIS (pH 7), 20% (v/v) glycerol and 1 mM TCEP. 
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Sample and baseline spectra were acquired at 5˚ C using 20 consecutive scans collected in 0.5 nm 
increments with a 1-nm bandwidth, a scanning speed of 50 nm/min, and a 4 s data integration time. 
The temperature dependence of the CD signal was measured between 5 and 90˚ C at 5˚ C intervals. 
Samples were heated at a rate of 2˚ C/min before three scans were recorded at each temperature. 
The spectra were averaged, baseline-corrected and smoothed using a Savitzky-Golay filter in the 
Spectra Manager software (Jasco).  
 
4.2.6 Binding affinity (Kd) determination of M3M4 
The Zn2+ stock solution was prepared in chelex-100 treated elution buffer and the concentration of 
Zn2+ was quantified using a terpyridine-Zn2+ titration159. The dissociation constant (Kd) for Zn2+ to 
FluoZin-3 was calculated as per the manufacturer’s instructions (Invitrogen). Briefly, 1.1 mM 
EGTA and 1.1 mM Zn2+ solutions were mixed to yield free Zn2+ concentrations from 0 to 100 nM, 
and these Zn2+ solutions were incubated with 1 µM FluoZin-3 in black 96-well plates (Thermo 
Scientific). Fluorescence was recorded on a Perkin Elmer VICTOR 1420 multilabel counter using 
a 485/14 excitation filter and a 535/25 emission filter. For competition assays with the purified 
M3M4 proteins, 1 µM FluoZin-3 and 1 µM Zn2+ were incubated with varying concentrations of 
M3M4 protein, and the fluorescence was measured. The Zn2+ dissociation constant for M3M4 was 
determined by fitting the curve to equation described below using GraphPad. 
𝐼𝐼𝐼𝐼50 = 𝐾𝐾𝐾𝐾(𝑀𝑀3𝑀𝑀4)[1 + [𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑛𝑛−3]
𝐾𝐾𝐾𝐾 (𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝑛𝑛−3)]     
where IC50 is the concentration of M3M4 required to reduce the maximum fluorescence by 50%, 
[FluoZin-3] is the concentration of FluoZin-3, and  Kd (FluoZin-3) is the experimentally determined 
Zn2+ dissociation constant for FluoZin-3. To fit the binding curves using GraphPad, the 
fluorescence was normalized, and the curves were fit by constraining the minimum and maximum 
normalized fluorescence values. The minimum fluorescence was obtained in the absence of zinc 
and maximum fluorescence was obtained in the absence of protein. 
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4.2.7 Atomic absorption spectroscopy 
Atomic absorption spectroscopy experiments were conducted by Dr. Elizabeth Bafaro. The purified 
M3M4 protein in elution buffer with an additional 1 mM TCEP was incubated with 4 molar 
equivalents of Zn2+ overnight at 4˚ C. Excess Zn2+ was removed by washing with chelex-100 treated 
20 mM Hepes, 20% (v/v) glycerol, 1 mM TCEP, pH 7 using 3 kDa molecular weight cut-off 
centricons (Millipore). The protein samples were diluted in 10% (v/v) nitric acid (trace metal-free) 
for AAS analysis. Zn2+ was quantified by graphite furnace atomic absorption spectroscopy (Perkin 
Elmer PiNNacle 900Z). Metal contents reported are the averages of at least three independent 
experiments. The metal content of proteins before Zn2+ addition was less than 0.1 moles Zn2+ per 
mole protein. 
 
4.2.8 X-ray absorption spectroscopy 
X-ray absorption spectroscopy was conducted by Tim Stemamler’s laboratory. M3M4 samples 
were prepared at final concentrations of 1 mM Zn2+ in 20 mM HEPES and 30% glycerol at pH 7.0.  
Samples were loaded into Lucite XAS sample cells wrapped with Kapton tape.  After loading, 
samples were flash frozen and stored in liquid N2 until data collection.  XAS data were collected at 
the National Synchrotron Light Source (NSLS), on beamline X3-b.  Beamline X3-b utilized a 
Si[111] single crystal monochromator equipped with a Ni plated harmonic rejection/focusing 
mirror.  During data collection, samples were maintained at 24˚ K using a He Displex Cryostat.  
Protein fluorescence excitation spectra were collected using a 31-element Ge solid-state detector, 
with a 0.6 μM Cu fluorescence filter placed between the cryostat and detector.  XAS spectra were 
measured in 5 eV increments in the pre-edge region (9600-9660 eV), 0.25 eV increments in the 
edge region (9,660-9740 eV) and 0.05 Å-1 increments in the extended X-ray absorption fine 
structure (EXAFS) region (to k = 14 Å-1), integrating from 1s to 25s in a k3 weighted manner for a 
total scan length of approximately 50 minutes.  X-ray energies were individually calibrated by 
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collecting Zn-foil absorption spectra simultaneously with the protein data.  The first inflection point 
of the Zn-foil spectrum was assigned to 9,668 eV.  Each fluorescence channel of each scan was 
examined for spectral anomalies, and data represent the average of 11 to 14 scans for each sample.  
 
XAS data were processed using the Macintosh OS X version of the EXAFSPAK program suite160 
integrated with the Feff v8 software package for theoretical model generation161. Data reduction 
utilized a Gaussian function in the pre-edge region and a three-region cubic spline throughout the 
EXAFS region.  Data were converted to k-space using a Zn E0 value of 9,668 eV. The k cubed 
weighted EXAFS was truncated at 1.0 and 13.5 Å-1 for filtering purposes.  This k range corresponds 
to a spectral resolution of ca. 0.115 Å for all zinc-ligand interactions; therefore only independent 
scattering environments outside 0.115 Å were considered resolvable in the EXAFS fitting 
analysis162. EXAFS fitting analysis was performed on raw/unfiltered data. EXAFS data were fit 
using both single and multiple scattering amplitude and phase functions calculated with the 
program Feff v8.  Single scattering theoretical models were calculated for carbon, nitrogen, oxygen, 
and sulfur coordination to simulate zinc nearest-neighbor ligand environments.  Scale factors (Sc) 
and E0 values used during the simulations were calibrated by fitting crystallographically 
characterized Zn models; specific values include a Scale Factor of 0.9, and E0 values for O, N, C 
and S of -15.54 eV were used in these simulations69. Criteria for judging the best-fit simulation 
utilized both the lowest mean square deviation between data and fit (F'), corrected for the number 
of degrees of freedom and a reasonable Debye-Waller factor163, 164. 
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4.3 Results 
4.3.1 The intracellular loop of hZIP4 is disordered 
The hZIP4 protein (Figure 28A) was analyzed using the disorder predictor FoldIndex155. The 
FoldIndex algorithm predicted that the majority of the hZIP4 protein is folded with the exception 
of the intracellular M3M4 loop (Figure 28B).  
 
In support of the prediction, the amino acid sequence of the intracellular M3M4 domain contains a 
low proportion (17%) of order-promoting amino acids (W, C, F, I, Y, V, L, N) and a high proportion 
(64%) of disorder-promoting residues (A, R, G, Q, S, P, E, K)165. To investigate the structural and 
functional properties of the large intracellular loop of hZIP4, we expressed the intracellular domain 
(residues 424-498 of the full-length hZIP4) fused to a Strep-tag in E. coli and purified the protein 
using a heat-cooling extraction method shown to improve the yield and purity for intrinsically 
disordered proteins157, 158. Following affinity purification, yields of 1 mg protein L-1 culture were 
obtained. N-terminal protein sequencing confirmed the identity of the purified protein as the M3M4 
domain (data not shown). The purified protein had a slower than predicted mobility on SDS-PAGE, 
migrating at an apparent molecular mass of 16 kDa (Figure 29), which is 1.4 times higher than the 
molecular mass calculated from the amino acid sequence (11.4 kDa). Slower mobilities in SDS-
PAGE have been observed for IDPs, which bind less SDS than globular proteins due to their unique 
amino acid compositions165.  
 
The disordered nature of the M3M4 domain was supported by far-UV circular dichroism (CD) 
spectroscopy. The CD spectrum (Figure 30) of the M3M4 domain showed a negative minimum at 
203 nm, indicative of a random coil structure, and a weak negative shoulder at 220 nm, which may 
indicate a small degree of α-helical structure.  Upon increasing the temperature from 5˚ C to 85˚ C, 
the CD spectra showed an isodichroic point at 208 nm (Figure 30B) which indicates that the M3M4 
protein undergoes small temperature-induced conformational change. In general, the  
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Figure 28. The hZIP4 domain structure and predicted regions of disorder. (A) Schematic of the 
hZIP4 transporter with the sequence of the large cytosolic loop M3M4 shown. Histidine residues 
are colored red, cysteine is colored green, acidic residues are colored blue, and the lysine residue 
is yellow. (B) FoldIndex prediction of disordered regions within the hZIP4 protein. Amino acid 
residues with a negative FoldIndex score (colored red) are considered as disordered while those 
with positive scores (colored green) are considered to be in ordered regions. 
 
 
 
A 
B 
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Figure 29. Purification of the recombinantly expressed M3M4 domain using the heat-cooling 
extraction method. Coomassie Blue stained SDS-PAGE gel of the purification fractions with 
molecular weight markers (M) indicated. After cell lysis using the heat-cooling extraction method, 
the cell lysate supernatant (LS) was applied to a Strep-Tactin column and the flow-through (FT) 
was collected. The column was washed with buffer (20 mM Hepes pH 8, 150 mM NaCl (W1) and 
20 mM Hepes pH 8, 20% glycerol (W2)), and the protein was eluted in buffer containing 
desthiobiotin  (E) 
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Figure 30. CD spectra of the purified M3M4 domain. The CD spectra was collected in 20 mM 
TRIS, pH 7 and 20 % (v/v) glycerol at (A) 5°C and (B) at increasing temperatures from 5˚ C to 85˚ 
C. Representative curves at 5˚ C (blue), 25˚ C (orange), 45˚ C (grey), 65˚ C (yellow) and 85˚ C 
(green) are shown.  
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CD data support the structural predictions that the intracellular M3M4 loop of hZIP4 is an 
intrinsically disordered region. 
 
4.3.2 The intracellular M3M4 domain binds Zn2+ with nanomolar affinity 
The number of Zn2+ ions that bind to the M3M4 domain was quantified by atomic absorption 
spectroscopy (AAS). For the AAS analysis, purified M3M4 protein was incubated with a four-fold 
molar excess of Zn2+ and loosely bound Zn2+ was removed by washing with buffer. As measured 
by AAS, the M3M4 domain binds Zn2+ with a stoichiometry of 2.2 ± 0.2 Zn2+ ions per protein 
molecule, demonstrating the presence of two binding sites for Zn2+ within the intracellular loop.  
 
To investigate the binding affinity of the M3M4 domain for Zn2+, FluoZin-3 was used as a Zn2+ 
chelator in competition assays with the protein166.  FluoZin-3 shows an increase in fluorescence 
upon binding Zn2+ with a 1:1 stoichiometry. The dissociation constant of FluoZin-3 (Kdfluozin) for 
Zn2+ was determined to be 21 ± 5 nM under our experimental conditions. The dissociation constant 
of FluoZin-3 for Zn2+ was determined individually for each experimental data set, and this value 
was used to fit the binding data within the same set of competition experiments. The M3M4 
dissociation constant for Zn2+ was measured using a competition experiment with FluoZin-3 as 
described previously166. In the competition experiments, equimolar amounts of FluoZin-3 and Zn2+ 
were titrated with purified M3M4 protein. The resulting competition data for the wild-type M3M4 
domain (Fig. 31A) were fit using one- and two-site binding models. Error analysis of the two 
models indicated that the one-site model provided the best fit for the data despite the measured 2:1 
Zn2+:protein stoichiometry observed for the M3M4 protein domain. This suggests either that the 
two Zn2+ ions bind to the M3M4 domain with similar affinities, which cannot be distinguished 
using the competition assay, or that the second Zn2+ ion binds to the protein with a much weaker 
binding affinity, which cannot be measured using the current assay method. Unfortunately, our 
attempts to measure a weaker Zn2+ binding affinity using a fluorescent indicator (Newport Green) 
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with a micromolar dissociation constant for Zn2+ were unsuccessful due to the tendency of the 
protein to aggregate at high Zn2+ concentrations as determined by dynamic light scattering 
experiments (data not shown). Thus, the intracellular M3M4 domain of the hZIP4 transporter binds 
at least one Zn2+ ion according to a one-site binding model with a macroscopic dissociation constant 
of 6 ± 1 nM (Fig. 31A).  
 
4.3.3 Histidine and cysteine residues are involved in Zn2+ binding in the M3M4 domain 
 Cysteine, histidine, and the acidic residues aspartate and glutamate most commonly coordinate 
Zn2+ 10. The M3M4 domain contains one cysteine, six histidine and 13 acidic residues (Fig. 28A). 
In order to determine the contributions of these residues in Zn2+ binding, the M3M4 protein was 
treated with N-ethylmaleimide (NEM), diethyl pyrocarbonate (DEPC), and N,N′-dicyclohexyl 
carbodiimide (DCCD), which selectively labels cysteine, histidine, and aspartate and glutamate 
residues, respectively. Following labeling, the Zn2+ binding stoichiometry and dissociation 
constants were measured. The results (Table 7) indicate that labeling the acidic residues with 
DCCD did not affect either the Zn2+:protein binding stoichiometry or the dissociation constant 
compared to the wild-type protein. However, labeling the protein with DEPC resulted in a complete 
loss of Zn2+ binding to the M3M4 protein as measured by AAS (Table 7). Consistent with this 
result, the dissociation constant for the DEPC-labeled protein could not be measured using the 
FluoZin-3 competition assay (Fig. 31B). A slight decrease in fluorescence signal was observed in 
the competition assay at high concentrations of the DEPC-treated M3M4 protein, which we 
postulate is the result of nonspecific interactions between the free Zn2+ and the protein. Finally, 
labeling the single cysteine residue in the M3M4 domain by treatment with NEM lowered the 
protein’s binding affinity for Zn2+ such that the dissociation constant could not be measured using 
the competition assay (Fig. 31C), although the NEM-treated protein was still able  
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Figure 31. Normalized competitive binding curves for the determination of Zn2+ dissociation 
constants to the wild-type, labeled and mutant M3M4 proteins. The fluorescence emitted in the 
presence of various concentrations of M3M4 was normalized to Fmax (the fluorescence of 1 µM 
Zn2+ and 1µM Fluozin-3) and dissociation constants were determined using a one-site binding 
model (Equation 1). (A) Fluorescence inhibition curve for wild-type M3M4 protein. Representative 
fluorescence inhibition curves comparing wild-type (circles) and (B) DEPC treated wild-type 
protein (squares), (C) NEM treated wild-type protein (squares), (D) H438A mutant protein 
(squares), (E) H441A mutant protein (squares), (F) C436A (squares), (G) C436A/H438A/H441A 
triple mutant protein (squares), and (H) H443A/H446A/H448A triple mutant protein (squares). 
Data are the average of the assay done in triplicate for one protein preparation. Three independent 
protein preparations gave equivalent results. Error bars represent ± one standard deviation. 
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Table 7. Zn(II) binding stoichiometry and dissociation constants for M3M4 
Protein Zinc:protein 
stoichiometry 
KD (nM) 
Labeling reagent   
   Unlabeled 2.2 ± 0.2 5 ± 1 (n=3) 
   DCCD 2.3 ± 0.2 6 ± 1 (n=3) 
   DEPC 0.3 ± 0.1 No binding (n=3) 
   N-ethyl maleimide 1.7 ± 0.3 N.D. (n=3) 
   
Mutation   
   Wild-type 2.2 ± 0.2 6 ± 1 (n=5) 
   C436A 2.2 ± 0.2 N.D. (n=3) 
   H438A 2.1 ± 0.1 8 ± 1 (n=3) 
   H441A 2.0 ± 0.3 9 ± 2 (n=3) 
   H443A 2.4 ± 0.2 7 ± 1 (n=3) 
   H446A 2.4 ± 0.2 6 ± 2 (n=3) 
   H448A 2.4 ± 0.4 6 ± 2 (n=3) 
   H466A 2.7 ± 0.2 5.6 ± 0.2 (n=3) 
   
   C436A/H438A/H441A 1.3 ± 0.2 N.D. (n=3) 
   H443A/H446A/H448A 1.1 0.2 12 ± 2 (n=3) 
 
N.D. – Weaker binding. The dissociation constant could not be determined using the competition 
assay. Bold-faced are significantly different from wild-type. 
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to bind 1.7 ± 0.3 Zn2+ per protein molecule when treated with an excess of Zn2+ (Table 7). Based 
on the labeling data, we conclude that the histidine and cysteine residues, but not aspartate or 
glutamate residues, coordinate Zn2+ in the intracellular M3M4 loop of hZIP4.  
 
To further investigate the role of the histidine and cysteine residues in Zn2+ coordination by M3M4, 
we individually mutated the six histidine and one cysteine residues to alanine. All single mutants 
retained the ability to bind two Zn2+ ions per molecule protein (Table 7). Interestingly, the H466A 
mutant protein was able to bind significantly higher amounts of Zn2+. Competition assays with 
FluoZin-3 were performed. As with the wild-type protein, the binding data for the single histidine 
mutations were best fit to a one-site binding model, and the dissociation constants were calculated 
(Table 7). The single mutants H443A, H446A, H448A and H466A showed Zn2+ binding affinities 
that were comparable to the wild-type protein, whereas the single mutants H438A and H441A 
displayed binding affinities that were statistically different (p values < 0.05) from the wild-type 
protein (Table 7, Figure 31D and E). Although the H438A and H441A mutant proteins exhibited 
weaker binding affinities compared to the wild-type, the change in dissociation constants was not 
as dramatic as observed for the DEPC-labeled protein. The inability of any single histidine mutation 
to produce a marked change in Zn2+ binding affinity is likely due to stabilization of the Zn2+ ion by 
the remaining histidines and neighboring residues. Ligand substitution by neighboring residues has 
also been observed in a Zn2+ finger protein167. In contrast to the histidine mutants, mutation of the 
single cysteine residue to alanine (C436A) resulted in a protein with a substantially weaker Zn2+ 
binding affinity that could not be measured using the FluoZin-3 competition assay (Figure 31F). 
Taken together, the single histidine and cysteine mutations in M3M4 indicated that C436, H438, 
and H441 are important residues contributing to Zn2+ binding. 
 
Based on the results of the single mutants, we designed two triple mutants, C436A/H438A/H441A 
and H443A/H446A/H448A, and analyzed these mutants for Zn2+ binding.  As expected, both triple 
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mutant proteins bound only one Zn2+ ion per molecule protein (Table 7). Also, the triple mutants 
showed significantly weaker Zn2+ binding affinities when compared to the wild-type domain (Table 
7, Figure 31G and H). In the case of the H443A/H446A/H448A triple mutant, the measured 
dissociation constant was two-fold higher than that of the wild-type protein, whereas the 
C436A/H438A/H441A triple mutant yielded a substantially weaker dissociation constant that could 
not be measured using the FluoZin-3 competition assay. These data suggest that C436/H438/H441 
and H443/H446/H448 likely form the two coordination sites for Zn2+ binding to the intracellular 
M3M4 domain, with the C436/H438/H441 having a tighter binding affinity for Zn2+. The binding 
affinity data suggest that Zn2+ binds first to the higher affinity C436/H438/H441 site, followed by 
binding of the second Zn2+ to the H443/H446/H448 site. 
 
4.3.4 EXAFS reveals the coordination geometry of Zn2+ bound to M3M4 (In collaboration 
with Timothy L. Stemmler Lab, Wayne State University) 
In order to further elucidate the Zn2+-binding properties of the M3M4 domain, the Zn2+-bound 
protein was analyzed by X-ray absorption spectroscopy (XAS). The X-ray absorption near edge 
structure (XANES) portion of an XAS spectrum provides qualitative details regarding metal site 
structure with ligand details regarding metal site structure with ligand speciation and can be used 
to compare differences in metal binding sites on related protein samples. XANES spectra of M3M4 
prepared with various stoichiometric amounts of Zn2+ revealed that the M3M4 protein with 0.5 and 
1 molar equivalent of Zn2+ yielded similar XANES spectra, whereas the two Zn2+-bound protein 
produced a distinctly different XANES edge (Figure 32A). These data are consistent with a model 
in which the two Zn2+ ions bind sequentially to the M3M4 domain. Further, simulations of the 
extended X-ray absorption fine structure (EXAFS) region of the XAS spectrum provide metrical 
details regarding the metal-ligand coordination environments for a metal in a metalloprotein at 
extremely high resolution (± 0.02 Å)._ENREF_61_ENREF_71163 EXAFS spectra for the Zn2+-
bound M3M4 proteins, along with the Fourier transforms of the EXAFS data, are given in Figure 
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33.  In each spectrum, the EXAFS at ca. k = 4 Å-1 shows a bead pattern characteristic of imidazole 
scattering from a histidine residue coordinated to the protein-bound metal._ENREF_69168 All 
spectra could be fit with nearest neighbor scattering constructed predominately with O/N ligands, 
and, in the case of M3M4 with 0.5 and 1 molar equivalent Zn2+, with an additional sulfur scattering 
ligand (Table 8). No sulfur ligation was observed in the M3M4 protein with two Zn2+ bound, 
presumably since the sulfur scattering is a low component of the overall ligand scattering signal. 
Within the error of technique (± 0.5), all Zn2+ coordination numbers from the simulations are 
consistent with Zn2+ being tetra-coordinated. Based on the EXAFS analysis, we conclude that the 
first Zn2+ ion binds to a CysHis3 site and the second Zn2+ ion binds to a site comprised solely of 
histidines. Long range scattering (R > 2.8 Å) is observed in the Fourier transforms of the samples, 
as expected given the suggested presence of imidazole coordination. Long-range scattering 
interactions could be easily simulated  for Zn2+-C/N interactions above R = 2.8 Å using single 
scattering models, however coordination numbers for the fits were variable and consistent with an 
overlap between single and multiple scattering contributions at each of the long range bond lengths. 
Attempts to fit this data with a multiple scattering theoretical model compound for a Zn2+-imidazole 
interaction were unsuccessful. 
 
XAS was also used to evaluate Zn2+ coordination in the triple mutants (C436A/H438A/H441A and 
H443A/H446A/H448A). XANES spectra of the H443A/H446A/H448A mutant resembled the one 
Zn2+-bound wild-type protein (Fig. 32B), and EXAFS data (Figure 33G, Table 7) showed the same 
CysHis3 coordination geometry as the wild-type protein with a single Zn2+ ion bound. The 
C436A/H438A/H441A mutant protein showed an XANES spectrum intermediate between the one 
and two Zn2+ bound wild-type (Figure 32B), and the EXAFS analysis revealed a ligand  
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Figure 32. Normalized XANES spectra for wild-type and triple mutant Zn2+-loaded M3M4 
samples.  (A) XANES spectra of wild-type M3M4 in the presence of 0.5 (gray line), 1 (black line) 
and 2 (dashed line) equivalents of Zn2+. (B) XANES spectra of C436A/H438A/H441A triple 
mutant (gray dashed line) and H443A/H446A/H448A triple mutant (gray dashed line) loaded with 
1 equivalent Zn2+ compared to wild-type M3M4 loaded with 1 (black solid line) or 2 (black dashed 
line) equivalents of Zn2+. 
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Figure 33. EXAFS and Fourier transform of the EXAFS data for wild-type and mutant Zn2+-loaded 
M3M4 proteins.  Comparison of raw data (black) and simulations (green) for both the EXAFS (left) 
and Fourier transform (right). Wild-type M3M4 with 0.5 equivalents of Zn2+ (A, B), wild- type 
with 1 equivalent of Zn2+ (C, D), wild-type with 2 equivalents of Zn2+ (E, F), 
C436A/H438A/H441A triple mutant (G, H), and H443A/H446A/H448A triple mutant (I, J). 
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Table 8. EXAFS and Fourier transform of the EXAFS data for wild-type and mutant Zn2+-loaded 
M3M4 proteins.  Comparison of raw data (black) and simulations (green) for both the EXAFS (left) 
and Fourier transform (right). Wild-type M3M4 with 0.5 equivalents of Zn2+ (A, B), wild- type 
with 1 equivalent of Zn2+ (C, D), wild-type with 2 equivalents of Zn2+ (E, F), 
C436A/H438A/H441A triple mutant (G, H), and H443A/H446A/H448A triple mutant (I, J). 
 
 
 
 
 
 
 
 
 
 
  
Nearest-Neighbor Ligand Environmenta 
 
Sample Fitb Atomc R(Å)d C.N.e σ2 f F' g 
Wild-type + 0.5 Zn2+ 1 O/N 2.01 2.5 
 
5.4 1.55 
 2 O/N 1.99 2.5 5.1 0.52 
  S 2.28 1.5 
 
5.1  
Wild-type + 1 Zn2+ 1 O/N 2.01 3.0 
 
4.6 1.90 
 2 O/N 1.99 3.0 4.0 1.41 
  S 2.28 1.0 
 
4.3  
Wild-type + 2 Zn2+ 1 O/N 1.99 3.5 
 
4.8 0.54 
C436A/H438A/H441A 1 O/N 1.98 4.0 
 
4.6 0.84 
H443A/H446A/H448A 1 O/N 2.01 3.0 
 
5.3 1.62 
 2 O/N 1.99 3.0 4.8 0.71 
  S 2.28 1.5 5.0  
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environment consisting of four histidine residues (Figure 33I, Table 8). Interestingly, addition of a 
second Zn2+ to the wild-type M3M4 protein distorts the average metal binding site away from a 
simple linear combination of the single loaded independent sites. Taken together, the XAS results 
are consistent with the model derived from mutagenesis analysis, in which two Zn2+ ions bind 
sequentially to two distinct sites within the M3M4 domain, with the CysHis3 site comprising the 
first site and a histidine only site comprising the second site. 
 
4.3.5 Structural changes to the M3M4 domain upon Zn2+ binding  
Structural changes to the intracellular domain upon Zn2+ binding were monitored by CD 
spectroscopy. Upon sequential addition of Zn2+ to M3M4, only minor changes in the CD spectra 
were observed (Figure 34). Interestingly, the M3M4 protein undergoes a small structural change 
upon binding the second Zn2+.  However, the presence of the large negative peak at 203 nm in all 
the spectra indicates that the M3M4 protein domain remains largely disordered even in the Zn2+-
bound state. 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Figure 34. Effect of Zn2+ on M3M4 CD spectra. The CD spectra of the M3M4 domain was 
collected presence of 0 (blue line), 1 (orange line) and 2 (grey line) molar equivalents of Zn2+.  
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4.4 Discussion 
In this study, our data provide the first direct evidence that the histidine-rich domain within the 
cytoplasmic M3M4 loop of hZIP4 binds two Zn2+ ions (Table 7). Moreover, we have shown by 
using XAS (Figure. 32 and 33) that Zn2+ binding occurs sequentially with the first Zn2+ binding to 
a site involving the single cysteine residue and three histidine residues (CysHis3) followed by a 
second Zn2+ binding event to a site consisting solely of histidine residues (His4). Based on the 
results of our mutagenesis analysis (Table 7), our data is consistent with the observation that single 
alanine replacement of histidine residues within the M3M4 domain does not eliminate zinc-
dependent degradation of hZIP496. Equally, from the analysis of this data, we conclude that the 
CysHis3 site is comprised of C436, H438 and H441, and the second site (His4) is likely composed 
of H443, H446 and H448 and a fourth ligand, which may be H466 (Figure 31). Although mutation 
of H466 to alanine did not affect the Zn2+ binding affinity, the H466A mutant protein consistently 
bound higher amounts of Zn2+ than the wild-type or any of the other single mutants. We, therefore, 
speculate that mutation of H466, increases the structural flexibility of the protein domain, which 
may allow more adventitious Zn2+ binding to the M3M4 domain (Figure 31A). The fourth histidine 
ligand for the CysHis3 site is likely a bridging ligand shared by the two sites. As Zn2+ ions are 
typically found in tetra-coordinated environments169, binding of two Zn2+ ions would require a 
minimum of seven protein ligands with one ligand serving as a bridge. Bridging ligands have been 
observed in other Zn2+ binding proteins; for example, cysteine is a bridging ligand in 
metallothionein170 and histidine serves as a bridging ligand in Cu, Zn superoxide dismutase171. 
Based on our data, we speculate that one of the histidines in the loop acts as a bridging ligand, but 
we cannot predict which histidine functions as the bridging ligand.    
 
Using the FluoZin-3 competition assay, we measured a single apparent dissociation constant of 6 
± 1 nM for Zn2+ binding to the isolated M3M4 intracellular domain (Table 7, Figure 31A). The 
measured one-site binding reflects Zn2+ binding to the CysHis3 site as the H443A/H446A/H448A 
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Figure 35. Proposed model of Zn2+ binding to M3M4 
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triple mutant displayed a binding affinity in the low nanomolar range, whereas a significantly 
weaker binding affinity binding that could not be measured using the Fluozin-3 indicator was 
observed for the C436A/H438A/H441A triple mutant. Thus, the first Zn2+ binds to the CysHis3 site 
with a low nanomolar binding affinity followed by binding of the second Zn2+ to the His4 site with 
a weaker, likely micromolar or higher, binding affinity. It should be noted that the dissociation 
constant measured for the purified M3M4 protein may not necessarily reflect the in vivo binding 
affinity of Zn2+ for this domain as interactions of the cytoplasmic loop with other regions of the 
hZIP4 transporter or with the lipid environment may modulate its affinity for Zn2+. Nevertheless, 
the low nanomolar Zn2+ binding affinity of the CysHis3 site within the M3M4 domain is comparable 
to other Zn2+-binding proteins whose measured Zn2+ dissociation constants range from nanomolar 
to low picomolar or less172. The cytoplasmic concentration of free Zn2+ in eukaryotic cells is 
estimated to be in the picomolar to low nanomolar range172, which suggests that the CysHis3 site 
may be occupied with Zn2+ under normal physiological conditions. The second, His4, site would be 
unoccupied at normal cytosolic free Zn2+ concentrations. The His4 site would become occupied 
with Zn2+ as the local Zn2+ concentration near the M3M4 domain is expected to be higher as hZIP4 
functions to transport Zn2+ across the membrane. Thus, we propose that the His4 site likely acts as 
a sensor to detect high cytosolic Zn2+ concentrations and control the level of hZIP4 in the plasma 
membrane accordingly. Only when both sites are occupied will hZIP4 be subjected to zinc-
stimulated ubiquitination and degradation96.   
 
To investigate the structural basis for Zn2+ sensing by the M3M4 loop, a combination of protein 
structure prediction algorithms and CD spectroscopy were used. The cytoplasmic M3M4 loop of 
hZIP4 was predicted (Figure 28B) and shown to be intrinsically disordered (Figure 30). It is 
possible that the M3M4 domain adopts a more defined structure within the holo-hZIP4 protein. 
However, analysis of the prediction algorithms and our data suggest that M3M4 is mostly 
disordered. As IDPs and IDPRs tend to undergo disorder-to-order transitions upon binding partner 
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molecules, we sought to determine if the M3M4 cytosolic loop becomes ordered upon Zn2+ binding 
using CD spectroscopy to assess secondary structure. The M3M4 protein domain remains largely 
disordered in the Zn2+-bound state (Figure 34). Recently, the occurrence of disorder in the bound 
state has been found to be a common feature of IDPs153, 173. More than 40 IDPs have been shown 
to form “fuzzy” complexes upon interaction with their partners173. “Fuzziness” is believed to be 
functionally advantageous, allowing IDPs or IDPRs the flexibility to interact with multiple partners 
or to undergo a variety of post-translational modifications, such as phosphorylation and 
ubiquitination153,173. Also, the S490 residue of hZIP4 was identified to be phosphorylated in an 
analysis of the phosphoproteome of human embryonic stem cells174. In addition to phosphorylation, 
hZIP4 was predicted using the UbPred server to undergo ubiquitination at K463 within the 
intracellular M3M4 loop175. hZIP4 was shown to be ubiquitinated at high cytosolic Zn2+ 
concentrations and to undergo subsequent proteasomal degradation of the transporter96. Taken 
together with our data on Zn2+ binding to the purified cytosolic domain, we propose a model 
whereby, at high cytosolic Zn2+ concentrations, Zn2+ binding to the low-affinity His4 site, combined 
with an occupied CysHis3 site, induces structural changes in the M3M4 intracellular loop, which 
may alter the post-translational modification status of hZIP4. Degradation in the proteasome is 
enhanced by the presence of a disordered protein region downstream of the ubiquitination site96, 176. 
 
The cytosolic loop of hZIP4 likely fulfills a number of roles, including proper processing and 
recycling of the transporter and possibly modulating Zn2+ transport through changes in post-
translational modifications, all of which rely on its disordered state. As disordered regions tend not 
to be under strong evolutionary conservation177, it is not surprising that the large cytosolic loop 
between transmembrane domains III and IV, which is characteristic of the LIV-I subfamily of ZIP 
transporters, is nonconserved. Among the human LIV-I subfamily members, the amino acid 
sequence and the number and arrangement of potential Zn2+ binding ligands varies. Thus, the 
cytosolic M3M4 domain likely functions as a protein-specific regulatory domain. 
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5. Future work 
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6.1 Define the driving force conditions for hZIP4 
Ion transport membrane proteins are largely classified under ion channels, ion pumps and ion 
transporters178. Ion channels have a well-defined pore and the selectivity of an ion is largely decided 
by physical interactions and pore size of the channel178. To open the pore and transport ions towards 
the concentration gradient, a small conformational change is required, where the energy 
requirement for inducing such change is very small178. The ion pumps require relatively more 
energy to pump the ions against the concentration gradient, which is derived from ATP 
hydrolysis178. The ion transporter has a thermodynamically more complex mechanism of transport. 
Transporters are highly selective for a distinct ligand and undergo a large conformational change 
upon binding 178. The large conformational change requires high energetic interactions, which is 
being provided via ATP hydrolysis or by means of other favorable binding energies178.  
 
Sequence homology analysis of hZIP4 has revealed that the protein does not have an ATP binding 
domain. Under these circumstances, the electrochemical gradient could provide energy to facilitate 
a large conformational change for hZIP4178. To eliminate the possibility of ion gradient facilitated 
zinc transport, we have used proton, sodium, potassium and chloride ion gradients. We have also 
used bicarbonate which has been reported as a co-transporter for hZIP2, hZIP8 and hZIP14. 
However, it is not clear what the driving force for zinc transport is. Interestingly, when using 
sodium citrate and sodium acetate to replace chloride, we found significant inhibition of transport 
activity. We could not rule out any conclusion based on this experiment since both these salts are 
known to reduce the intracellular pH and have a chelating effect as well. At this point, we cannot 
deny the possibility of hZIP4 being governed by intracellular conditions. By manipulating 
intracellular conditions such as changing intracellular salt concentration and pH, we can test the 
hypothesis of hZIP4 mediated transport in governed by intracellular ion gradients. However, using 
X. laevis oocytes for such experiments is not a viable option because of the stability of oocytes. To 
address all the challenges associated with hZIP4 driving force, we can express and purify the hZIP4 
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protein heterologously in P. pastoris. Successful reconstitution of the hZIP4 protein into the 
liposomes would provide us with more flexibility with respect to testing conditions such as salt 
gradient and pH both inside and outside.  
 
6.2 Oligomeric state of hZIP4 
In this study, we have shown that hZIP4 may functions as a dimer. Our analysis is based on the 
effect of reducing agent during sample preparation of an SDS-PAGE gel. The oligomeric state of 
hZIP4 should be more definitively tested by a more direct approach. One such approach to test for 
the oligomeric state is with total internal reflection fluorescence microscopy, where hZIP4 is tagged 
with a fluorescence protein and the photo-bleaching effect is tracked against the time. The photo-
bleaching pattern is directly corresponding to the oligomeric state of protein179. However, one needs 
to be careful about the results as steric interference may interfere with the formation of dimer. An 
alternative approach could be cysteine cross-linking experiment180.  
 
 
 
 
 
 
 
 
 
116 
 
 
 
 
 
 
 
 
 
 
 
 
6. References 
 
 
 
 
 
 
 
 
 
 
 
 
117 
 
1. J. Raulin, Ann. Sci. Nat., 1869, 11, 93-99. 
2. A. Prasad, J. Lab. Clin. Med., 1963, 61, 537-549. 
3. A. S. Prasad, A. R. Schulert, A. Miale, Z. Farid and H. H. Sandstead, Am. J. Clin. Nutr., 
1963, 12, 437-444. 
4. H. H. Sandstead, A. S. Prasad, A. R. Schulert, Z. Farid, A. Miale, S. Bassilly and W. J. Darby, 
Am. J. Clin. Nutr., 1967, 20, 422-442. 
5. A. S. Prasad, Am. J. Clin. Nutr., 1991, 53, 403-412. 
6. G. J. Fosmire, Am. J. Clin. Nutr., 1990, 51, 225-227. 
7. W. Maret and A. Krężel, Mol. Med., 2007, 13, 371-375. 
8. P. Zalewski, I. Forbes, R. Seamark, R. Borlinghaus, W. Betts, S. Lincoln and A. Ward, 
Chem. Biol., 1994, 1, 153-161. 
9. Y. Li and W. Maret, Exp. Cell Res., 2009, 315, 2463-2470. 
10. W. Maret and Y. Li, Chem. Rev., 2009, 109, 4682-4707. 
11. R. A. Bozym, R. B. Thompson, A. K. Stoddard and C. A. Fierke, ACS Chem. Biol., 2006, 1, 
103-111. 
12. M. Foster, R. Leapman, M. Li and I. Atwater, Biophys. J., 1993, 64, 525-532. 
13. C. Andreini, L. Banci, I. Bertini and A. Rosato, J. Proteome Res., 2006, 5, 196-201. 
14. K. A. McCall, C.-c. Huang and C. A. Fierke, J. Nutr., 2000, 130, 1437S-1446S. 
15. B. L. Vallee and D. S. Auld, Biochemistry, 1990, 29, 5647-5659. 
16. W. N. Lipscomb and N. Sträter, Chem. Rev., 1996, 96, 2375-2434. 
17. K. Patel, A. Kumar and S. Durani, Biochim. Biophys. Acta, 2007, 1774, 1247-1253. 
18. J. M. MatÉs, C. Pérez-Gómez and I. N. De Castro, Clin. Biochem., 1999, 32, 595-603. 
19. L. J. Machlin and A. Bendich, FASEB J., 1987, 1, 441-445. 
20. S. R. Powell, J. Nutr., 2000, 130, 1447S-1454S. 
21. W. Maret, J. Nutr., 2000, 130, 1455S-1458S. 
22. J. C. King, D. M. Shames and L. R. Woodhouse, J. Nutr., 2000, 130, 1360S-1366S. 
23. J. P. Liuzzi and R. J. Cousins, Annu. Rev. Nutr., 2004, 24, 151-172. 
24. S. Ripa and R. Ripa, Minerva Med., 1994, 86, 37-43. 
25. K. H. Brown, S. E. Wuehler and J. M. Peerson, Food Nutr. Bull., 2001, 22, 113-125. 
26. M. N. Hughes and R. K. Poole, Microbiology, 1991, 137, 725-734. 
27. R. J. Cousins, J. P. Liuzzi and L. A. Lichten, J. Biol. Chem., 2006, 281, 24085-24089. 
28. S. R. Davis and R. J. Cousins, J. Nutr., 2000, 130, 1085-1088. 
29. U. Rana, R. Kothinti, J. Meeusen, N. M. Tabatabai, S. Krezoski and D. H. Petering, J. Inorg. 
Biochem., 2008, 102, 489-499. 
30. W. Maret, Proc. Natl. Acad. Sci. USA, 1994, 91, 237-241. 
31. H. Shen, H. Qin and J. Guo, Nutr. Res., 2008, 28, 406-413. 
32. Y. Li and W. Maret, J. Anal. At. Spectrom., 2008, 23, 1055-1062. 
33. C. J. Haney, G. Grass, S. Franke and C. Rensing, J. Ind. Microbiol. Biotechnol., 2005, 32, 
215-226. 
34. T. Kambe, H. Narita, Y. Yamaguchi-Iwai, J. Hirose, T. Amano, N. Sugiura, R. Sasaki, K. 
Mori, T. Iwanaga and M. Nagao, J. Biol. Chem., 2002, 277, 19049-19055. 
35. T. Fukada and T. Kambe, Metallomics, 2011, 3, 662-674. 
36. L. A. Gaither and D. J. Eide, in Zinc Biochemistry, Physiology, and Homeostasis, Springer, 
2001, pp. 65-84. 
37. M. Lu and D. Fu, Science, 2007, 317, 1746-1748. 
38. I. Lasry, Y. Golan, B. Berman, N. Amram, F. Glaser and Y. G. Assaraf, J. Biol. Chem., 2014, 
289, 7275-7292. 
39. A. Michalczyk, J. Allen, R. Blomeley and M. Ackland, Biochem. J, 2002, 364, 105-113. 
118 
 
40. Y. Chao and D. Fu, J. Biol. Chem., 2004, 279, 12043-12050. 
41. E. Ohana, E. Hoch, C. Keasar, T. Kambe, O. Yifrach, M. Hershfinkel and I. Sekler, J. Biol. 
Chem., 2009, 284, 17677-17686. 
42. M. Quadri, A. Federico, T. Zhao, G. J. Breedveld, C. Battisti, C. Delnooz, L.-A. Severijnen, 
L. D. T. Mammarella, A. Mignarri and L. Monti, Am. J. Hum. Genet., 2012, 90, 467-477. 
43. M. L. Guerinot, Biochim. Biophys. Acta, 2000, 1465, 190-198. 
44. K. M. Taylor and R. I. Nicholson, Biochim. Biophys. Acta, 2003, 1611, 16-30. 
45. K. Wang, B. Zhou, Y.-M. Kuo, J. Zemansky and J. Gitschier, Am. J. Hum. Genet., 2002, 71, 
66-73. 
46. W. Chowanadisai, D. M. Graham, C. L. Keen, R. B. Rucker and M. A. Messerli, Proc. Natl. 
Acad. Sci. USA, 2013, 110, 9903-9908. 
47. K. Taylor, H. Morgan, A. Johnson, L. Hadley and R. Nicholson, Biochem. J, 2003, 375, 51-
59. 
48. T. P. Dalton, L. He, B. Wang, M. L. Miller, L. Jin, K. F. Stringer, X. Chang, C. S. Baxter and 
D. W. Nebert, Proc. Natl. Acad. Sci. USA, 2005, 102, 3401-3406. 
49. N. A. Begum, M. Kobayashi, Y. Moriwaki, M. Matsumoto, K. Toyoshima and T. Seya, 
Genomics, 2002, 80, 630-645. 
50. K. Taylor, H. Morgan, A. Johnson and R. Nicholson, FEBS Lett., 2005, 579, 427-432. 
51. N. Zhao, J. Gao, C. A. Enns and M. D. Knutson, J. Biol. Chem., 2010, 285, 32141-32150. 
52. F. Wang, B.-E. Kim, M. J. Petris and D. J. Eide, J. Biol. Chem., 2004, 279, 51433-51441. 
53. B. L. Mihelich, E. A. Khramtsova, N. Arva, A. Vaishnav, D. N. Johnson, A. A. Giangreco, E. 
Martens-Uzunova, O. Bagasra, A. Kajdacsy-Balla and L. Nonn, J. Biol. Chem., 2011, 286, 
44503-44511. 
54. N. Kagara, N. Tanaka, S. Noguchi and T. Hirano, Cancer Sci., 2007, 98, 692-697. 
55. K. Taylor, H. Morgan, A. Johnson and R. Nicholson, Biochem. J, 2004, 377, 131-139. 
56. L. Huang, C. P. Kirschke, Y. Zhang and Y. Y. Yu, J. Biol. Chem., 2005, 280, 15456-15463. 
57. B.-H. Bin, T. Fukada, T. Hosaka, S. Yamasaki, W. Ohashi, S. Hojyo, T. Miyai, K. Nishida, S. 
Yokoyama and T. Hirano, J. Biol. Chem., 2011, 286, 40255-40265. 
58. B. Milon, D. Dhermy, D. Pountney, M. Bourgeois and C. Beaumont, FEBS Lett., 2001, 507, 
241-246. 
59. L. A. Gaither and D. J. Eide, J. Biol. Chem., 2001, 276, 22258-22264. 
60. M. M. Desouki, J. Geradts, B. Milon, R. B. Franklin and L. C. Costello, Mol. Cancer, 2007, 
6, 37. 
61. L. A. Gaither and D. J. Eide, J. Biol. Chem., 2000, 275, 5560-5564. 
62. W. Matsuura, T. Yamazaki, Y. Yamaguchi-Iwai, S. Masuda, M. Nagao, G. K. Andrews and 
T. Kambe, Biosci. Biotechnol. Biochem., 2009, 73, 1142-1148. 
63. D. J. Eide, Pflügers Archiv, 2004, 447, 796-800. 
64. M.-C. Franz, A. Simonin, S. Graeter, M. A. Hediger and G. Kovacs, J. Biomol. Screen., 
2014, 19, 909-916. 
65. R. A. Colvin, C. P. Fontaine, D. Thomas, T. Hirano, T. Nagano and K. Kikuchi, Arch. 
Biochem. Biophys., 2005, 442, 222-228. 
66. C. Hogstrand, P. Kille, R. I. Nicholson and K. M. Taylor, Trends Mol. Med., 2009, 15, 101-
111. 
67. K. Girijashanker, L. He, M. Soleimani, J. M. Reed, H. Li, Z. Liu, B. Wang, T. P. Dalton and 
D. W. Nebert, Mol. Pharmacol., 2008, 73, 1413-1423. 
68. J. Dufner-Beattie, S. J. Langmade, F. Wang, D. Eide and G. K. Andrews, J. Biol. Chem., 
2003, 278, 50142-50150. 
119 
 
69. J. Dufner-Beattie, F. Wang, Y.-M. Kuo, J. Gitschier, D. Eide and G. K. Andrews, J. Biol. 
Chem., 2003, 278, 33474-33481. 
70. L. He, K. Girijashanker, T. P. Dalton, J. Reed, H. Li, M. Soleimani and D. W. Nebert, Mol. 
Pharmacol., 2006, 70, 171-180. 
71. Z. Liu, H. Li, M. Soleimani, K. Girijashanker, J. M. Reed, L. He, T. P. Dalton and D. W. 
Nebert, Biochem. Biophys. Res. Commun., 2008, 365, 814-820. 
72. P. Kaler and R. Prasad, Am J. Physiol. Renal Ph., 2007, 292, F217-F229. 
73. Y. Yu, A. Wu, Z. Zhang, G. Yan, F. Zhang, L. Zhang, X. Shen, R. Hu, Y. Zhang and K. Zhang, 
J. Nutr. Biochem., 2013, 24, 1697-1708. 
74. J. J. Pinilla-Tenas, B. K. Sparkman, A. Shawki, A. C. Illing, C. J. Mitchell, N. Zhao, J. P. 
Liuzzi, R. J. Cousins, M. D. Knutson and B. Mackenzie, Am. J. Physiol. Cell Ph., 2011, 301, 
C862-C871. 
75. S. Küry, B. Dréno, S. Bézieau, S. Giraudet, M. Kharfi, R. Kamoun and J.-P. Moisan, Nat. 
Genet., 2002, 31, 239-240. 
76. S. Schmitt, S. Küry, M. Giraud, B. Dréno, M. Kharfi and S. Bézieau, Hum. Mutat., 2009, 
30, 926-933. 
77. V. Garza-Rodríguez, C. Liy-Wong, S. Küry, S. Schmitt, I. S. Jamall and J. Ocampo-Candiani, 
Pediatr. Dermatol., 2015, 32, e124-e125. 
78. W. Maret and H. H. Sandstead, J. Trace Elem. Med. Biol., 2006, 20, 3-18. 
79. A. S. Prasad, Adv. Nutr., 2013, 4, 176-190. 
80. T. Donahue and O. J. Hines, Cancer Biol. Ther., 2010, 9, 243-245. 
81. M. Li, Y. Zhang, Z. Liu, U. Bharadwaj, H. Wang, X. Wang, S. Zhang, J. P. Liuzzi, S.-M. Chang 
and R. J. Cousins, Proc. Natl. Acad. Sci. USA, 2007, 104, 18636-18641. 
82. B. P. Weaver, Y. Zhang, S. Hiscox, G. L. Guo, U. Apte, K. M. Taylor, C. T. Sheline, L. Wang 
and G. K. Andrews, PLoS One, 2010, 5, e13158. 
83. Y. Lin, Y. Chen, Y. Wang, J. Yang, V. F. Zhu, Y. Liu, X. Cui, L. Chen, W. Yan, T. Jiang, G. W. 
Hergenroeder, S. A. Fletcher, J. M. Levine, D. H. Kim, N. Tandon, J.-j. Zhu and M. Li, 
Neuro Oncol., 2013, 15, 1008-1016. 
84. Y. Zhang, U. Bharadwaj, C. D. Logsdon, C. Chen, Q. Yao and M. Li, Clin. Cancer. Res., 
2010, 16, 1423-1430. 
85. S. Küry, M. Kharfi, R. Kamoun, A. Taïeb, E. Mallet, J. J. Baudon, C. Glastre, B. Michel, F. 
Sebag and D. Brooks, Hum. Mutat., 2003, 22, 337-338. 
86. A. Nakano, H. Nakano, K. Nomura, Y. Toyomaki and K. Hanada, J. Invest. Dermatol., 
2003, 120, 963-966. 
87. S. Kilic, M. Giraud, S. Schmitt, S. Bézieau and S. Küry, Br. J. Dermatol., 2007, 157, 386-
387. 
88. A. B. Hardy, K. J. Prentice, S. Froese, Y. Liu, G. K. Andrews and M. B. Wheeler, PLoS One, 
2015, 10, e0119136. 
89. Y. Liu, B. Batchuluun, L. Ho, D. Zhu, K. J. Prentice, A. Bhattacharjee, M. Zhang, F. 
Pourasgari, A. B. Hardy and K. M. Taylor, J. Biol. Chem., 2015, 290, 18757-18769. 
90. P. V. Hornbeck, B. Zhang, B. Murray, J. M. Kornhauser, V. Latham and E. Skrzypek, 
Nucleic Acids Res., 2015, 43, D512-D520. 
91. K. M. Taylor, S. Hiscox, R. I. Nicholson, C. Hogstrand and P. Kille, Sci. Signal., 2012, 5, 
ra11. 
92. S. S. Krishna, I. Majumdar and N. V. Grishin, Nucleic Acids Res., 2003, 31, 532-550. 
93. T. Kambe and G. K. Andrews, Mol. Cell. Biol., 2009, 29, 129-139. 
94. S. Ehsani, A. Salehzadeh, H. Huo, W. Reginold, C. L. Pocanschi, H. Ren, H. Wang, K. So, C. 
Sato and M. Mehrabian, J. Mol. Biol., 2012, 422, 556-574. 
120 
 
95. F. Wang, B.-E. Kim, J. Dufner-Beattie, M. J. Petris, G. Andrews and D. J. Eide, Hum. Mol. 
Genet., 2004, 13, 563-571. 
96. X. Mao, B.-E. Kim, F. Wang, D. J. Eide and M. J. Petris, J. Biol. Chem., 2007, 282, 6992-
7000. 
97. B.-E. Kim, F. Wang, J. Dufner-Beattie, G. K. Andrews, D. J. Eide and M. J. Petris, J. Biol. 
Chem., 2004, 279, 4523-4530. 
98. M. L. Bernhardt, B. Y. Kong, A. M. Kim, T. V. O'Halloran and T. K. Woodruff, Biol. Reprod., 
2012, 86, 114. 
99. T. Fukada, S. Yamasaki, K. Nishida, M. Murakami and T. Hirano, J. Biol. Inorg. Chem., 
2011, 16, 1123-1134. 
100. E. L. Que, R. Bleher, F. E. Duncan, B. Y. Kong, S. C. Gleber, S. Vogt, S. Chen, S. A. Garwin, 
A. R. Bayer, V. P. Dravid, T. K. Woodruff and T. V. O'Halloran, Nat. Chem., 2015, 7, 130-
139. 
101. C. Lorenz, M. Pusch and T. J. Jentsch, Proc. Natl. Acad. Sci. USA, 1996, 93, 13362-13366. 
102. R. Richards and R. E. Dempski, J. Vis. Exp., 2011, e2627. 
103. R. A. Valentine, K. A. Jackson, G. R. Christie, J. C. Mathers, P. M. Taylor and D. Ford, J. 
Biol. Chem., 2007, 282, 14389-14393. 
104. R. D. Palmiter and S. D. Findley, EMBO J., 1995, 14, 639. 
105. G. Dahl, E. Levine, C. Rabadan-Diehl and R. Werner, Eur. J. Biochem., 1991, 197, 141-144. 
106. S. Sheng, C. J. Perry and T. R. Kleyman, J. Biol. Chem., 2002, 277, 50098-50111. 
107. C. Clarke, C. Benham, A. Bridges, A. George and H. Meadows, J. Physiol., 2000, 523, 697-
703. 
108. J. G. Reyes, Am. J. Physiol. Cell Ph., 1996, 270, C401-C410. 
109. L. C. Costello, C. C. Fenselau and R. B. Franklin, J. Inorg. Biochem., 2011, 105, 589-599. 
110. J. F. Da Silva and R. J. P. Williams, The biological chemistry of the elements: the inorganic 
chemistry of life, Oxford University Press, 2001. 
111. V. L. Mendoza and R. W. Vachet, Anal. Chem., 2008, 80, 2895-2904. 
112. A. Gupta and S. Lutsenko, Future Med. Chem., 2009, 1, 1125-1142. 
113. H. Zhao and D. Eide, Proc. Natl. Acad. Sci. USA, 1996, 93, 2454-2458. 
114. H. Zhao and D. Eide, J. Biol. Chem., 1996, 271, 23203-23210. 
115. K. T. Simons, I. Ruczinski, C. Kooperberg, B. A. Fox, C. Bystroff and D. Baker, Proteins: 
Struct. Funct. Bioinform., 1999, 34, 82-95. 
116. H. Kamisetty, S. Ovchinnikov and D. Baker, Proc. Natl. Acad. Sci. USA, 2013, 110, 15674-
15679. 
117. A. R. Ortiz, A. Kolinski and J. Skolnick, J. Mol. Biol., 1998, 277, 419-448. 
118. K. Katoh, K. Misawa, K. i. Kuma and T. Miyata, Nucleic Acids Res., 2002, 30, 3059-3066. 
119. R. C. Edgar, Nucleic Acids Res., 2004, 32, 1792-1797. 
120. C. B. Do, M. S. Mahabhashyam, M. Brudno and S. Batzoglou, Genome Res., 2005, 15, 
330-340. 
121. A. Krogh, M. Brown, I. S. Mian, K. Sjölander and D. Haussler, J. Mol. Biol., 1994, 235, 
1501-1531. 
122. S. Raman, R. Vernon, J. Thompson, M. Tyka, R. Sadreyev, J. Pei, D. Kim, E. Kellogg, F. 
DiMaio, O. Lange, L. Kinch, W. Sheffler, B. H. Kim, R. Das, N. V. Grishin and D. Baker, 
Proteins: Struct. Funct. Bioinform., 2009, 77, 89-99. 
123. N. Coudray, S. Valvo, M. Hu, R. Lasala, C. Kim, M. Vink, M. Zhou, D. Provasi, M. Filizola, J. 
Tao, J. Fang, P. A. Penczek, I. Ubarretxena-Belandia and D. L. Stokes, Proc. Natl. Acad. 
Sci. USA, 2013, 110, 2140-2145. 
124. J. Söding, Bioinformatics, 2005, 21, 951-960. 
121 
 
125. P. Barth, J. Schonbrun and D. Baker, Proc. Natl. Acad. Sci. USA, 2007, 104, 15682-15687. 
126. V. Yarov-Yarovoy, P. G. DeCaen, R. E. Westenbroek, C.-Y. Pan, T. Scheuer, D. Baker and 
W. A. Catterall, Proc. Natl. Acad. Sci. USA, 2012, 109, E93-E102. 
127. Q. Cong and N. V. Grishin, BMC Biol., 2012, 10, 82. 
128. O. F. Lange, P. Rossi, N. G. Sgourakis, Y. Song, H.-W. Lee, J. M. Aramini, A. Ertekin, R. 
Xiao, T. B. Acton, G. T. Montelione and D. Baker, Proc. Natl. Acad. Sci. USA, 2012, 109, 
10873-10878. 
129. Y. Zhang and J. Skolnick, Proteins: Struct. Funct. Bioinform., 2004, 57, 702-710. 
130. F. DiMaio, A. Leaver-Fay, P. Bradley, D. Baker and I. André, PLoS One, 2011, 6, e20450. 
131. K. L. Dürr, N. N. Tavraz, R. E. Dempski, E. Bamberg and T. Friedrich, J. Biol. Chem., 2009, 
284, 3842-3854. 
132. M. Lazdunski, C. Petitclerc, D. Chappelet and C. Lazdunski, Eur. J. Biochem., 1971, 20, 
124-139. 
133. D. Sanders, J. Membr. Biol., 1986, 90, 67-87. 
134. J. Xu and Y. Zhang, Bioinformatics, 2010, 26, 889-895. 
135. Y. Zhang and J. Skolnick, Nucleic Acids Res., 2005, 33, 2302-2309. 
136. T. A. Hopf, L. J. Colwell, R. Sheridan, B. Rost, C. Sander and D. S. Marks, Cell, 2012, 149, 
1607-1621. 
137. T. Nugent and D. T. Jones, Proc. Natl. Acad. Sci. USA, 2012, 109, E1540-E1547. 
138. C. H. Wu, R. Apweiler, A. Bairoch, D. A. Natale, W. C. Barker, B. Boeckmann, S. Ferro, E. 
Gasteiger, H. Huang, R. Lopez, M. Magrane, M. J. Martin, R. Mazumder, C. O'Donovan, 
N. Redaschi and B. Suzek, Nucleic Acids Res., 2006, 34, D187-D191. 
139. D. Kozma, I. Simon and G. E. Tusnády, Nucleic Acids Res., 2013, 41, D524-D529. 
140. B. P. Pedersen, H. Kumar, A. B. Waight, A. J. Risenmay, Z. Roe-Zurz, B. H. Chau, A. 
Schlessinger, M. Bonomi, W. Harries, A. Sali, A. K. Johri and R. M. Stroud, Nature, 2013, 
496, 533-536. 
141. L. R. Gabriel, S. Wu and H. E. Melikian, J. Vis. Exp., 2013. 
142. Y. Wei and D. Fu, J. Biol. Chem., 2006, 281, 23492-23502. 
143. R. E. Dempski, Curr Top Membr, 2012, 69, 221-245. 
144. W. Lin, J. Chai, J. Love and D. Fu, J. Biol. Chem., 2010, 285, 39013-39020. 
145. M. G. Madej, S. Dang, N. Yan and H. R. Kaback, Proc. Natl. Acad. Sci. USA, 2013, 110, 
5870-5874. 
146. M. G. Madej and H. R. Kaback, Proc. Natl. Acad. Sci. USA, 2013, 110, E4831-E4838. 
147. Å. Västermark, B. Lunt and M. Saier, J. Mol. Microbiol. Biotechnol., 2014, 24, 82-90. 
148. Å. Västermark and M. H. Saier, Proc. Natl. Acad. Sci. USA, 2014, 111, E1162-E1163. 
149. V. N. Uversky, Protein Sci., 2013, 22, 693-724. 
150. T. Flock, R. J. Weatheritt, N. S. Latysheva and M. M. Babu, Curr. Opin. Struct. Biol., 2014, 
26, 62-72. 
151. B. Xue, L. Li, S. O. Meroueh, V. N. Uversky and A. K. Dunker, Mol Biosyst, 2009, 5, 1688-
1702. 
152. Y. Minezaki, K. Homma and K. Nishikawa, J. Mol. Biol., 2007, 368, 902-913. 
153. J. Habchi, P. Tompa, S. Longhi and V. N. Uversky, Chem. Rev., 2014, 114, 6561-6588. 
154. L. A. Lichten and R. J. Cousins, Annu. Rev. Nutr., 2009, 29, 153-176. 
155. J. Prilusky, C. E. Felder, T. Zeev-Ben-Mordehai, E. H. Rydberg, O. Man, J. S. Beckmann, I. 
Silman and J. L. Sussman, Bioinformatics, 2005, 21, 3435-3438. 
156. R. Kim, S. J. Sandler, S. Goldman, H. Yokota, A. J. Clark and S.-H. Kim, Biotechnol. Lett., 
1998, 20, 207-210. 
157. S. Yi, A. Brickenden and W.-Y. Choy, Protein Expr. Purif., 2008, 57, 1-8. 
122 
 
158. F. Campos, G. Guillén, J. L. Reyes and A. A. Covarrubias, Protein Expr. Purif., 2011, 80, 47-
51. 
159. S. C. Burdette, G. K. Walkup, B. Spingler, R. Y. Tsien and S. J. Lippard, J. Am. Chem. Soc., 
2001, 123, 7831-7841. 
160. G. George and I. Pickering, EXAFSPAK: A Suite of Computer Programs for Analysis of X-
ray Absorption Spectra, Stanford Synchrotron Radiation Laboratory, Stanford, CA, 2000. 
161. J. Rehr and A. Ankudinov, J. Synchrotron. Radiat., 2001, 8, 61-65. 
162. P. J. Riggs-Gelasco, T. L. Stemmler and J. E. Penner-Hahn, Coord. Chem. Rev., 1995, 144, 
245-286. 
163. K. Z. Bencze, K. C. Kondapalli and T. L. Stemmler, in Applications of Physical Methods to 
Inorganic and Bioinorganic Chemistry, 2007, pp. 513-528. 
164. J. J. Cotelesage, M. J. Pushie, P. Grochulski, I. J. Pickering and G. N. George, J. Inorg. 
Biochem., 2012, 115, 127-137. 
165. P. Tompa, Trends Biochem. Sci., 2002, 27, 527-533. 
166. L. M. De León-Rodríguez, A. J. Lubag, J. A. López, G. Andreu-de-Riquer, J. C. Alvarado-
Monzón and A. D. Sherry, Med. Chem. Commun., 2012, 3, 480-483. 
167. C. A. Blasie and J. M. Berg, Inorg. Chem., 2000, 39, 348-351. 
168. T. L. Stemmler, T. M. Sossong, J. I. Goldstein, D. E. Ash, T. E. Elgren, D. M. Kurtz and J. E. 
Penner-Hahn, Biochemistry, 1997, 36, 9847-9858. 
169. M. Laitaoja, J. Valjakka and J. Jänis, Inorg. Chem., 2013, 52, 10983-10991. 
170. G. Meloni, K. Zovo, J. Kazantseva, P. Palumaa and M. Vašák, J. Biol. Chem., 2006, 281, 
14588-14595. 
171. H. E. Parge, R. A. Hallewell and J. A. Tainer, Proc. Natl. Acad. Sci. USA, 1992, 89, 6109-
6113. 
172. T. Kochańczyk, A. Drozd and A. Krężel, Metallomics, 2015, 7, 244-257. 
173. M. Fuxreiter and P. Tompa, Adv. Exp. Med. Biol., 2012, 725, 1-14. 
174. L. M. Brill, W. Xiong, K.-B. Lee, S. B. Ficarro, A. Crain, Y. Xu, A. Terskikh, E. Y. Snyder and 
S. Ding, Cell Stem Cell, 2009, 5, 204-213. 
175. P. Radivojac, V. Vacic, C. Haynes, R. R. Cocklin, A. Mohan, J. W. Heyen, M. G. Goebl and 
L. M. Iakoucheva, Proteins: Struct. Funct. Bioinform., 2010, 78, 365-380. 
176. S. Prakash, L. Tian, K. S. Ratliff, R. E. Lehotzky and A. Matouschek, Nat. Struct. Mol. Biol., 
2004, 11, 830-837. 
177. C. J. Brown, A. K. Johnson, A. K. Dunker and G. W. Daughdrill, Curr. Opin. Struct. Biol., 
2011, 21, 441-446. 
178. G. R. Dubyak, Adv. Physiol. Ed., 2004, 28, 143-154. 
179. A. Penna, A. Demuro, A. V. Yeromin, S. L. Zhang, O. Safrina, I. Parker and M. D. Cahalan, 
Nature, 2008, 456, 116-120. 
180. M. Mense, P. Vergani, D. M. White, G. Altberg, A. C. Nairn and D. C. Gadsby, EMBO J., 
2006, 25, 4728-4739. 
 
 
